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ABSTRACT
FORECASTING PRESCRIPTION OF MEDICATIONS AND COST ANALYSIS
USING TIME SERIES ANALYSIS
Mussie Angesom Tesfamicael
August 04 2007

The purpose of this research study is to examine the use of time series
forecasting and text mining to investigate the prescription of antibiotics. The
specific objective is to examine the relationship between the total payments,
private insurance payments, Medicare payments, Medicaid payments, number of
prescriptions and quantity of prescriptions for different antibiotics. Currently,
there is no method available to forecast antibiotic prescription costs, so we have
adopted several methods that will help health care providers and hospitals to
know about the prescription of the antibiotics being prescribed. The payment
made for each antibiotic is based upon an average cost and total cost that will
include the cost of the antibiotics and insurance payments. It will be beneficial to
show health care providers the trends of these antibiotics in terms of the cost
analysis. It is also beneficial to make comparisons between several antibiotics in
terms of the number of prescriptions and to do further study as to why one
antibiotic is prescribed more often than others.

v

We developed time series models that will be used to forecast the prescription
practices of the antibiotics. The time series models that we developed for
antibiotic prescription are; simple exponential smoothing models, double
exponential smoothing model, linear exponential smoothing model. We used
exponential models to develop forecasting for antibiotics on which cost increases
exponentially. We also developed an autoregressive integrated moving average
model for non-stationary data on which the series has no constant mean and
variance through time. We developed Generalized Autoregressive Conditional
Heteroskedastic Models for volatile variance, and we also incorporated the
inflation rate as a model dynamic regressor to see the effect on model forecast.
We finally used text mining and clustering to classify the ICD-9 codes into six
clusters and make comparisons within each cluster, by plotting the data using
kernel density estimation. This project will be beneficial for health care
institutions for predicting the trend of the antibiotic prescription, so that further
studies can be made why one antibiotic is prescribed more often than others.
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CHAPTER 1
INTRODUCTION

The purpose of this project is to develop time series models to investigate
prescribing practices and patient usage of antibiotics with respect to the severity
of the patient condition. The cost of antibiotics is rising from year to year; some
antibiotics are prescribed more often compared to others even if they have
similar properties. It would be of interest to pharmaceutical companies to know
the reason for this.

It is the purpose of this project to examine trends and patterns in the prescribing
of antibiotic antibiotics. We want to determine whether prescribing patterns
change over time, and whether costs change as well. We will develop time
series models for each antibiotic to investigate physician practices.

Time series methods have been used to investigate prescribing practices, usually
to examine compliance with guidelines.1 However, these approaches do not yet
take into consideration the more recently developed transactional time series
methods that can be used with electronic information from the prescription
database; for example, information from Pyxis Products (Pyxis Products; San-

1

Diego, CA) can be downloaded directly and used to investigate prescribing
practices.1,2 One popular time series tool is that of interrupted time series
analysis to investigate the impact of an intervention.3

The patient condition is defined by a list of ICD9 (International classification of
disease) codes developed by the World Health Organization5. The ICD9 codes
are a series of 5-digit numbers with the first 3 digits representing the main
condition and the last 2 digits representing specifics of the condition. For
example, “599” represents other disorders of the urethra and urinary tract and
“599.55” represents operations on the renal pelvis.

It is the purpose of this research to develop time series models to predict the cost
of antibiotics, private insurance payments, Medicaid payments, Medicare
payments, the quantity of antibiotics, total payment and to study why the cost is
rising in one antibiotic compared to others. We will also investigate how much
patients are spending on average for their prescriptions of antibiotics. The data
set we have does not take the inflation rate into account, but in this study, we will
use the inflation rate as a time-dependent regressor to forecast the cost of
antibiotics. Both forecasts, the one that incorporates the inflation rates and the
one that does not will be compared. We will compare the cost of antibiotics with
respect to the inflation rates.
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It is noteworthy that some drugs are called by their generic or brand names. The
generic drug name is the chemical name of a drug referring to the chemical
makeup of a drug rather than to the advertised brand name under which the drug
is sold.6

There are over 100 antibiotics in the market, but the majority of them come from
only a few types of drugs. The main classes of antibiotics are Penicillin such as
penicillin and Amoxicillin, Cephalosporin such as Cephalexin (Keflex), Macrolides
such as erythromycin, Clarithromycin and Azithromycin (Zithromax),
Fluoroquinolones such as ciprofloxacin (Cipro), Levoflaxacin (Levaquin), and
Tetracycline such as Tetracycline and Doxycycline (Vibramycin). In this project,
we will study the cost analysis of these antibiotics in relation to time 9.

The data set was obtained from the Medical Expenditure Panel Survey (MEPS)
on prescribed antibiotics, using data from 1996-2004, with 2004 the most current
year posted. The data for each year is contained in a separate dataset, for
instance, the prescribed antibiotics for the year 1996 is on file HC-010A; this file
contains the patient’s antibiotic information and cost for the drugs.4 The other
datasets also contain information for one of the years, 1997-2004. Information is
merged for all the years to have a single dataset. The preprocessing is
described in detail in chapter 2.
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Antibiotics are among the most frequently prescribed medications nowadays.
Antibiotics cure disease by killing or injuring bacteria. The first discovered
antibiotic was penicillin, which was discovered from a mold culture. Today, over
100 different antibiotics are available to doctors to cure minor discomforts as well
as life-threatening infections.

Antibiotics only treat bacterial infection, although they are used in a wide variety
of illnesses. Antibiotics don’t cure viral infections such as the common cold; nor
can they treat fungal infections9. Most antibiotics have two names, a brand name
created by the drug company that manufactures the drug and a generic name
based on the chemical composition of the drug.

Previous studies

Prescription drugs account for 19.88 percent of total health care expenditures for
the U.S. civilian, non-institutionalized population for the years 2003 and 2004.
The prescription expenditure was 11.9 percent of total health expenditures in
1996. The increase of the overall costs of health care has a direct effect on the
increase of the cost of prescription drugs; as a result, more attention has been
given to studying these costs. The percentage of total health care expenditures
for prescription drugs increased from 11.5 percent in 1996 to 19.5 percent in both
2003 and 2004 for persons under the age of 65 7.

4

The average expense per purchase for brand name and generic medications has
increased over the years, 1999 to 2003, with the average expense for generic
medication rising from $23.48 to $33.53 and the average expense for a brand
name drug rising from $59.49 to $82.53 8.

Previous studies have not developed time series models to investigate the cost
and prescription practices for medications. This research will also define a
measure to classify the severity of a patient’s condition using ICD9 codes.

Purpose of the Study

The main purpose of this study is to develop time series models to forecast the
cost of antibiotics and to classify patient usage of antibiotics with respect to
patient conditions using text-mining clustering. We will also study on average
how much patients are spending on antibiotics.

Another purpose of this research is the changing behavior of the cost of
antibiotics by introducing intervention variables. We will analyze these data
using interrupted time series analysis. We also examine the payments made for
Medicare and Medicaid and study how much patients are spending on average
for prescriptions. We also want to clear that we have only studied the antibiotic
prescription of the several medications that are available in the market.
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In this dissertation, we develop time series models, such as ARIMA models, ESM
(Exponential Smoothing Model), and the Heteroskedastic models (ARCH and
GARCH). Autoregressive procedures are used to develop a model for each
antibiotic so that cost can be forecast. We also use data mining techniques, in
particular, text mining to classify the prescriptions based on the patient’s severity
conditions using ICD9 codes. Text mining is used to classify observations based
on the content of the words listed in each variable with the expectation
maximization algorithm (EM).

This dissertation is organized as follows: Chapter two gives detailed information
about how we preprocessed the data. Chapter three introduces the Exponential
smoothing models (ESM). ESM starts with an infinite past and applies a
weighted average with weights that exponentially decay to zero. Chapter four
describes in detail the theory of ARIMA models. Chapter five is about
Heteroskedastic models. It analyzes and forecasts for volatile time series data.
Chapter six describes the theory of text mining and classification. Chapter seven
shows the results of our analyses through several different models. Statistical
data analysis and figures will be used throughout to determine the best model.
Chapter eight gives the summary, conclusion and recommended follow-up
studies.

6

CHAPTER 2
DATA PROCESSING
In this chapter, we give a detailed discussion of how the data were preprocessed
before a model for prediction was built. Most studies that involve simulation do
not require preprocessing. The researcher has to generate random data and
build a specific model that fits the data generated. However, in time series
analysis, one has to preprocess the data before a model for prediction is built. In
particular, in this project, a large amount of time was required to preprocess the
data. The data set for this project was collected from the medical expenditure
panel survey (MEPS) 4. The MEPS contains new and extensive data on the use
of health services and health care in the United States. MEPS is conducted to
provide nationally representative estimates of health care use, expenditures,
sources of payment, and insurance coverage for the U.S. civilian noninstitutionalized population.

MEPS consist of three surveys. The Household Component (HC) is the core
survey and forms the basis for the Medical Provider Component (MPC) and part
of the Insurance Component (IC). The MEPS household component (HC) survey
collects data through contact with a household by a series of five rounds of
interviews over a two and half year period. Data are collected each year on a
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new sample of households to provide current estimates of health care
expenditures.

The MEPS medical provider component (MPC) add-on certifies information on
medical care events reported in the MEPS HC by contacting medical providers
and pharmacies identified by household respondents. The MPC sample includes
all hospitals, hospital physicians, home health agencies, and pharmacies
reported in the MEPS-HC. The MPC is conducted through telephone interviews
and mailed survey materials. Sometimes, providers sent medical and billing
records that were abstracted into the survey instruments.

The MEPS insurance component (IC) collects data on health insurance plans
obtained through employers, unions, and other sources of private health
insurance. Data obtained in the IC include the number and types of private
insurance plans offered, benefits associated with these plans, premiums,
contributions by employers and employees, eligibility requirements, and
employer characteristics.

Together, these surveys yield comprehensive data that provide national
estimates of the level and distribution of health care use and expenditures,
support health services research, and can be used to assess health care policy
implications.
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The data set we used consisted of the Medical Expenditure Panel Survey
(MEPS) information on prescribed antibiotics, using data from 1996-2004, with
2004 the most current year posted. The MEPS prescription antibiotics datasets
consist of the following datasets for the years 1996-2004:
HC-010A

1996

HC-016A

1997

HC-026A

1998

HC-033A

1999

HC-051A

2000

HC-059A

2001

HC-067A

2002

HC-077A

2003

HC-085A

2004

These datasets were in SAS transport format, so the following code was written
to import the data directly into SAS:
Libname Tseries V8 'F:\Dissertation';
FILENAME IN1 'F:\Disertation\H51A.SSP';
PROC XCOPY IN=IN1 OUT=TSERIES IMPORT;
RUN;
SAS CODE 1
Table 2.1 SAS code used to transport dataset in SAS format

For each data set, we created a STARTMEDDATE (start date of antibiotic), and
the number of prescriptions for each antibiotic (DRUG). The following SAS code
was written:
9

DATA SASUSER.H33A1;
SET SASUSER.H33A;
KEEP DUID RXBEGDD RXBEGMM RXBEGYR STARTMEDDATE RXICD1X
PURCHRD RXNAME RXQUANTY
RXMRX RXMDX RXPVX RXXPX DRUG;
IF RXBEGDD THEN DO;
RXBEGDD=ABS (RXBEGDD);
STARTMEDDATE=MDY (RXBEGMM, RXBEGDD, RXBEGYR);
END;
IF RXQUANTY >0 THEN DO;
DRUG=1;
END; RUN;
SAS CODE 2
Table 2.2 SAS code used to create the format of the dataset

Table 2.3 gives the description of the variables for the dataset, antibiotics. We
have mentioned earlier that the variable, STARTMEDDATE, was formed by
concatenating RXBEGDD (day antibiotic taken), RXBEGMM (month antibiotic
taken), and RXBEGYR (year antibiotic taken).

10

Variable

DESCRIPTION

DUID

Unique Person Identifier

RXQUANTY

Quantity of prescribed antibiotic

RXMRX

Amount paid by Medicare

RXMDX

Amount paid by Medicaid

RXPVX

Amount paid by private insurance

RXXPX

Total amount paid (Cost of antibiotic)

STARTMEDDATE

Start date of antibiotic

RXICD1X

ICD9-CODE

Table 2.3. The variables and their descriptions

We created a time series variable by merging the day, month and year of each
prescription with the label, STARTMEDDATE. If one of these three values is
missing, there will be a missing value for STARTMEDDATE. A missing day is
replaced by the beginning of the month and a missing month and year were
deleted from the dataset; otherwise, imputing a value might distort the time series
of the data.

We then merged each year’s data set to create an antibiotics dataset for the
years 1996-2004 combined. The following SAS code was written to do the task.
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data Sasuser.Antibiotics;
length DUID 8 PURCHRD 8 RXBEGDD 8 RXBEGMM 8 RXBEGYR 8
RXNAME $ 50 RXQUANTY 8 RXICD1X $ 3 RXMRX 8 RXMDX 8 RXPVX8
RXXPX 8 STARTMEDDATE 8 DRUG 8;
Set Tseries.H10a Tseries.H16a Tseries.h26a Tseries.h33a Tseries.h51a
Tseries.h59a Tseries.h67a Tseries.h77a Tseries.h85a Tseries.hc10a ;
keep DUID PURCHRD RXBEGDD RXBEGMM RXBEGYR RXNAME
RXQUANTY RXICD1X RXMRX RXMDX RXPVX RXXPX
STARTMEDDATE DRUG;
run;
SAS CODE 3
Table 2.4 SAS code used to merge the dataset for each year

When the variable to be analyzed is text, each text is considered as a single
variable level. For instance, Keflex 500MG and Keflex 250MG will be considered
two different antibiotics if the text is not changed to Keflex. In order to avoid this
problem for each antibiotic investigated in this project, we did filter to a commonly
known antibiotic. The following code was written:

12

PROC SQL; CREATE TABLE SASUSER.ANTIBIOTICSFiltered AS SELECT
Sasuser.DUID FORMAT=BEST12, Sasuser.PURCHRD FORMAT=BEST12.,
Sasuser.RXBEGDD FORMAT=BEST12.,
Sasuser.RXBEGMM FORMAT=BEST12.,
Sasuser.RXBEGYR FORMAT=BEST12.,
Sasuser.RXNAME FORMAT=$F50., Sasuser.RXQUANTY FORMAT=BEST12.,
Sasuser.RXICD1X FORMAT=$F3.,
Sasuser.RXMRX FORMAT=BEST12., Sasuser.RXMDX FORMAT=BEST12.,
Sasuser.RXPVX FORMAT=BEST12., asuser.RXXPX FORMAT=BEST12.,
Sasuser.STARTMEDDATE FORMAT=DATE9.,
Sasuser.DRUG FORMAT=BEST12.,
((CASE WHEN "KEFLEX 250MG"=Sasuser.RXNAME THEN "KEFLEX"
WHEN "KEFLEX 500MG"= Sasuser.RXNAME THEN "KEFLEX"
WHEN "KEFLEX (CEPHELEXIN)"= Sasuser.RXNAME THEN "KEFLEX"
WHEN "KEFLEX - GENERIC"= Sasuser.RXNAME THEN "KEFLEX"
datalines deleted …
WHEN "LEVAQUIN (FILM-COATED)"= Sasuser.RXNAME THEN "LEVAQUIN"
WHEN "LEVAQUIN 500MG"= Sasuser.RXNAME THEN "LEVAQUIN"
WHEN "LEVAQUIN 500MG TABS*50"= Sasuser.RXNAME THEN "LEVAQUIN"
WHEN "LEVAQUIN LEVA-PAK (3X5,FILM-COATED)"= Sasuser.RXNAME
THEN "LEVAQUIN"
ELSE Sasuser.RXNAME END )) AS Recode_RXNAME
FROM SASUSER.Antibiotics AS Antibiotics; QUIT;
SAS CODE 4
Table 2.5 SAS code used to match observations
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Once the dataset was processed and filtered, we selected a set of antibiotics. An
antibiotic is a drug that kills or prevents the growth of bacteria but has no effect
against viruses or fungal infections. Antibiotics are less harmful to the patient or
host compared to the infection, and therefore, can be used to treat infection.

When analyzing time series data, each observation should have a unique
identifier such that this identifier is the time upon which the event happened. Due
to scenarios that a patient might receive prescription antibiotics multiple numbers
of times during the time interval under study, there might be several transactions
made at a unique time point. Our data set has multiple prescriptions at the same
time point, and time series models don’t analyze such transactional data.
Therefore, we converted the time identifier by accumulating the observations
monthly, with the seasonal period set at 12 months.
The time period used to accumulate data points depends on what the forecaster
wants to know. For instance, if we want to know the average number of
prescriptions made during a month, then the accumulation will be an average.
Since not every month has an equal numbers of days, we divide the total
prescriptions made by the number of days in that particular month. On the other
hand, if the forecaster wants to know the total number of prescriptions made
during a particular month, then the accumulation point will be a sum. The
accumulation point also could be the median, standard deviation, and so forth.
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Accumulating data points depends on the specific research question needed to
be addressed.

Figure 2.1. The Prescription Data of Antibiotics.

Figure 2.1 represents the format of the antibiotics data set analyzed in this
project. We can see that there are four transactions made on September 12,
1996. This is an indication of the data set as a transactional series. Time series
only analyze equal time intervals; as a result, we accumulated the data. As the
main aim of this study is to analyze prescription practices of antibiotics monthly,
we forced the accumulation point to be total (Figure 2.2). It is of interest to know
the average number of prescriptions of antibiotics, so we accumulated on
average (Figure 2.3). When data are accumulated monthly, the total amount in
that month is divided by the number of days in that month. SAS Code 5 and SAS
15

Code 6 create a time series for antibiotic data by accumulating total and average
respectively.

proc hpf data=data.amoxicillin out=sasuser.amoxicilintotal lead=0;
id startmeddate interval=month accumulate=TOTAL;
forecast RXQUANTY RXMRX RXMDX RXPVX RXXPX;
by Rxname;
run;
SAS CODE 5
Table 2.6 SAS code to create dataset Amoxicillin accumulation of monthly prescriptions

Figure 2.2. The monthly prescriptions of Antibiotics
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proc hpf data=data.amoxicillin out=sasuser.amoxicilinaverage lead=0;
id startmeddate interval=month accumulate=Average;
forecast RXQUANTY RXMRX RXMDX RXPVX RXXPX;
by Rxname;
run;
SAS CODE 6
Table 2.7 SAS code to create dataset Amoxicillin accumulation of average

Figure 2.3 Average prescriptions of Antibiotics

In this project, we will build a time series model to study the trend of prescription
antibiotics. We selected a set of antibiotics to be analyzed based on the
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availability of enough data points. This is due to the fact that some antibiotics are
less prescribed compared to others and there are not enough data points
collected to examine some of the sparsely used antibiotics. As a result, we
selected a set of 20 antibiotics to investigate the trend of prescription practices of
antibiotics. The description of the list of antibiotics investigated in this project is
given in table 2.7.

Antibiotics
Amoxicillin
Antibiotics Cefadroxil

Ampicillin

Azithromycin Cefaclor

Cefuroxime

Cephalexin

Cipro

Clotrimazole

Dicloxacillin

Clarithromycin Clindamycin
Doxycycline

Erythromycin Keflex

Sulfamethroxazole

Tequin

Tetracycline

Vancomycin

Tobramycin

Table 2.8 Antibiotics Investigated for model forecast

Discussion

In this chapter, we have discussed how to prepare messy data for analysis. A
statistical model analyzes a dataset to answer the research question of interest.
In this project, we will build time series models to study and forecast prescription
practices of antibiotics. Since we are building time series models, the dataset
must have the form of time series data. A time series dataset is characterized by
a series of fixed width time points. However, our dataset was transactional,
18

without any fixed time points. As a result, we preprocessed the dataset to have a
format of time series. Once the messy dataset has time series variables, a
model can be built to forecast and study the prescription practices of antibiotics.
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CHAPTER 3

EXPONENTIAL SMOOTHING MODELS

Exponential smoothing is a class of techniques in time series analysis.
Exponential smoothing produces good forecasts because it contains a selfadjusting mechanism for previous forecast errors, and because it assigns
weights to previous data. In exponential smoothing, we assume that the future
characteristics of the variable (Medicare, for example) are influenced by the past
behavior of the variable. The main difference of exponential smoothing models
from other time series models, for example ARIMA models, is that exponential
smoothing assumes that a more recent event of a variable has more influence on
future behavior compared to the distant past 12.

Exponential smoothing models are used as an extension of weighted averages.
The mean of the observations is the sum of the numbers divided by the total
number of observations. Mathematically,

Y =

Y
Y Y
1 n
1
Yt = (Y1 + Y2 + Λ + Yn ) = 1 + 2 + Λ + n
∑
n n
n
n t =1
n
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(3.1)

The weight for each variable Yt in equation (3.1) is equal to

1
, where Yt is the
n

time series point at time t . Now, if we assume each Yt is independent and
identically distributed, then equation (3.1) is the best predictor of the next
observed value, Yt +1 , using a criterion such as least squares or maximum
likelihood. But in a time series, not all values have the same weight; recent
values might have more weight compared to more distant values. Therefore, the
general weighted average can be written as

n

Yˆ = ∑ wt Yt ,
t =1

n

∑w
t =1

t

= 1.

(3.2)

If the sample mean is used to forecast future values, the model used will be

Yt = µ + ε t

(3.3)

where ε t ~ N (0, σ 2 ) , E (ε t , ε j ) = 0 , and t ≠ j . If we assign a weight of one to the
most recent observation, and a weight of zero to all other observations, we get a
random walk model where the best predictor is the most recent observation, and
all past observations provide no additional information to improve the prediction.
Mathematically, the equation for a random walk model is
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Yt = Yt −1 + ε t

(3.4)

where ε t ~ N (0, σ 2 ) , and if the random walk is moved by an average, the
mathematical equation will be

Yt = µ + Yt −1 + ε t

(3.5)

Equation (3.5) is called a random walk with a drift.

If we compromise between the mean model and the random walk model, we get
an exponential smoothing model where the weights exponentially decay to zero
as we use older and older observations. To derive the equation for exponential
smoothing models, we start with an infinite past and apply a weighted average
with weights that exponentially decay to zero.

Given a time series Yt for t = 1,2,..., n , the model assumed by the smoothing
model has the following form:

Yt = µ t + β t t + s p (t ) + ε t

(3.6)
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where µ t represents the time varying mean term, β t represents the time-varying
slope, s p (t ) represents the time-varying seasonal contribution for one of the p
seasons and ε t represent disturbances.

If the smoothing model of equation (3.6) doesn’t have trend terms, then β t = 0 ,
and for a smoothing model without seasonal terms, s p (t ) = 0 . If the smoothing
model doesn’t have time varying slope and time-varying seasonality, then
equation (3.6) reduces to equation (3.3), which is the mean model.

The smoothing model estimates the time-varying components at each time t with
the smoothing state. After initializing, the smoothing state is updated for each
observation using the smoothing equations. The smoothing state at the last nonmissing observation is used for prediction.

Smoothing State and Smoothing Equations

The smoothing equations determine how the smoothing state changes with
increasing time. If we know the smoothing state at time t-1 and the time series
value at time t, we can uniquely determine the smoothing state at time t. We
have several smoothing models, but the smoothing state at time t consists of the
following: Lt is a smoothed level that estimates µ t , Tt is a smoothed trend that
estimates β t and S t − j , j = 0,1,..., p − 1 are seasonal factors that estimate s p (t ) .
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Once we have the smoothing equation, we need to initialize the smoothing state.
Let y t be a time series where t = 1,2,..., n . Then the smoothing process first
computes the smoothing state for time t=1. This computation requires an initial
estimate of the smoothing state at time t=0, in which no data exist before time
t=0. Therefore, we need to make an appropriate initial smoothing state where we
back cast from the last time points, say t=n to t=1 to get a prediction at t=0. The
smoothing state at time t=0 obtained from the back cast is used to initialize the
smoothing process from time t=1 to t=n 10.

Seasonal Exponential Models

Exponential smoothing models give more weight to recent observations instead
of to distant observations. Seasonal time series have strong autocorrelations
that go far back into the past; therefore, simple exponential smoothing models
don’t capture seasonal effects. But if we add a seasonal component, then we
can use the exponential smoothing model. The seasonal exponential smoothing
method does not have a trend component.

An additive model is of the form Yt = µ t + s p (t ) + ε t , where µ t is the linear term
and s p (t ) is the seasonal term. A multiplicative model (Winter’s) is of the form

Yt = ( µ t + β t t ) s p (t ) + ε t , which is the product of the linear term and the seasonal
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term. For the additive model, the seasonal factors sum to one, while for the
multiplicative model, the seasonal factors average to one. For models with
p −1

seasonal terms, we normalize the smoothing state so that

∑S
j =0

that assume additive seasonality, and

t− j

= 0 for models

1 p −1
∑ S t − j = 1 for models that assume
p j =0

multiplicative seasonality such as Winter’s method.

Statistically speaking, every model we build has an error term. The model that
will be built for forecasting has to have a minimal error, i.e. the predictions should
be made with minimal error. Predictions are made based on the last known
value of the smoothing state.

Let Yˆt (k ) denote the prediction made at time t for k steps ahead, and let et (k )
denote the prediction error, where et (k ) = Yt + k − Yˆt (k ) . As an example, a one step
ahead prediction can be made at time t − 1 for one time unit into the future, which
can be denoted as Yˆt −1 (1) . The one step-ahead prediction errors can be denoted
by et = et −1 (1) = Yt − Yˆt −1 (1) . The data set analyzed for this project has some
missing values at certain time points. When a missing value is obtained by
chance at time t, the smoothed values are updated using the error-correction
form of the smoothing equations with the one step-ahead prediction error, et , set
to zero. The missing value is estimated using the one-step-ahead prediction at
time t-1, i.e. Yˆt −1 (1) 11.
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Exponential smoothing models are categorized into four basic models. They are
the simple exponential smoothing model, the double exponential smoothing
model, the linear exponential smoothing model and the damped trend
exponential smoothing model.

Simple Exponential Smoothing Model
Given a time series Yt , where t = 1,2,..., n , the model equation for simple
exponential smoothing is given by

Yt = µ t + ε t

(3.7)

The smoothing equation is given by

Yˆt +1 = ωYt + ω (1 − ω )Yt −1 + ω (1 − ω ) 2 Yt − 2 + ω (1 − ω ) 3 Yt −3 + ...

If we factor out

(1−ω) from equation (3.8), then we will have

Yˆt +1 = ωYt + (1 − ω )[ωYt −1 + ω (1 − ω )Yt − 2 + ω (1 − ω ) 2 Yt −3 + ...] ;

hence, equation (3.8) can be reduced to
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(3.8)

Yˆt +1 = ωYt + (1 − ω )Yˆt

where

(3.9)

ω is the exponential weight.

Double (Brown) Exponential Smoothing Model

A double exponential smoothing model is applied to the data if a trend or
seasonal factors appear in the data. A trend can be either increasing or
decreasing. Double exponential smoothing considers a sequence of regression
coefficients weighted more heavily towards the recent past.

The model equation for double exponential smoothing is

Yt = β 0 + β1t + ε t

(3.10)

where β 0 and β 1 vary with time. The prediction for k units in the future from
time t can be expressed in terms of a seasonal factor S t and trend term Tt .
Mathematically, the seasonal term can be expressed as S t = ωS t + (1 − ω ) S t −1 and
the trend term is expressed as Tt = ωS t + (1 − ω )Tt −1 ; hence, the double
exponential smoothing model can be expressed as:
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⎛
⎛
ωk ⎞
ωk ⎞
⎟⎟Tt
⎟⎟ S t − ⎜⎜1 +
Yˆt + k = ⎜⎜ 2 +
1−ω ⎠
⎝ 1−ω ⎠
⎝

(3.11)

ω
(S t − Tt ) and an estimate
The estimate of the slope at time t is given by βˆ1t =
1−ω
of intercept at time t is given by βˆ0t = 2 S t − Tt − tβˆ1t . When we have real data
with a trend and seasonality, the double exponential smoothing model will be
applied where starting values for the slope and intercept are initialized. The

⎛1− ω ⎞ ˆ
starting values for the slope and intercept are S 0 = βˆ0, 0 − ⎜
⎟ β1,0 and
⎝ ω ⎠
⎛1− ω ⎞
T0 = βˆ0, 0 − 2⎜
⎟ β̂1,0 respectively.
⎝ ω ⎠

Linear (Holt) Exponential Smoothing Model

The linear exponential smoothing model employs two time varying parameters
while double exponential smoothing employs a time varying linear regression
model that only relies on one smoothing parameter. As with the double
exponential smoothing model, a linear exponential smoothing model is applied to
model data with trend and seasonality.

28

For the linear (Holt) exponential smoothing, we begin with the same linear model
as double exponential smoothing. However, a second parameter γ (trend
smoothing weight) is added to equation (3.11). The model equation for double
exponential smoothing is given by:

Yˆt + k = S t + kTt

(3.12)

where S t = ωYt + (1 − ω )( S t −1 + Tt −1 ) and Tt = γ ( S t − S t −1 ) + (1 − γ )Tt −1 .

Damped Trend Linear Exponential Smoothing Model
A damped trend linear exponential smoothing model is a modification to the
linear (Holt) exponential smoothing model where the contribution of past trend is
dampened or reduced. Adding a third parameter φ (damping coefficient) to
equation (3.12) gives damped trend linear exponential smoothing. The model
equation for damped trend linear exponential smoothing is given by:

⎡k ⎤
Yˆt + k = S t + ⎢∑ φ i ⎥Tt
⎣ i =1 ⎦

(3.13)

where S t = ωYt + (1 − ω )( S t −1 + φTt −1 ) and Tt = γ ( S t − S t −1 ) + (1 − γ )φTt −1 .
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Discussion

Exponential smoothing is one of several techniques in time series forecasting
models. It is characterized by giving heavier weights to recent events and lower
weights to past events. To reduce forecasting error, an optimal smoothing
constant ( ω ) needs to be chosen. The ideal situation is to vary the smoothing
constant ( ω ) until the prediction error is minimal. The main point we have to
keep in mind is that regardless of which exponential model is chosen (simple,
double, linear and damped trend), the exponential model we build has to
minimize the residual (actual value-forecasted value).

To demonstrate the use of exponential smoothing models, we will build model
forecasts for the antibiotics dataset. According the nature of the time series, one
of the exponential smoothing models will be built to forecast antibiotic
prescriptions. Once the exponential smoothing model is built for the antibiotic
dataset, the forecasted values will be clustered into several clusters and
compared to each other based on the severity of the disease.
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Chapter 4

ARIMA MODELS

A time series that is a linear function of p past values plus an error is called an
autoregressive process of order p , denoted by AR( p) .

Yt = φ1Yt −1 + φ 2Yt − 2 + ... + φ p Yt − p + ε t

(4.1)

where φ1 , φ 2 ,..., φ p are constants and ε t is a white noise series with mean zero

and variance

σ ε2 .

A time series that is a linear function of q past errors is called a moving average
process of order q , denoted by MA(q) .

Yt = ε t + θ1ε t −1 + θ 2 ε t − 2 + ... + θ q ε t − q

(4.2)

where θ1 ,θ 2 ,...,θ q are parameters that determine the overall pattern of the
process and ε t is a white noise. A time series that is a linear function of p past
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values plus a linear combination of q past errors is called an autoregressive
moving average (ARMA) process of order ( p, q ) , denoted by ARMA( p, q) :

Yt = φ1Yt −1 + φ 2Yt − 2 + ... + φ p Yt − p + ε t + θ1ε t −1 + θ 2 ε t − 2 + ... + θ q ε t − q

(4.3)

Sometimes an ARMA model is called a mixture model, i.e. a mixture of
autoregressive and moving average parts. Another thing to be checked when
building an ARMA model is to see if the series is stationary. A time series is
stationary if the mean and variance of the series is constant at all time points.

Box-Jenkins (1976) modeling (also called ARIMA modeling) removes the nonstationary components such as trend and seasonality, and modeling the
stationary part that is left over. Therefore, if a time series has a nonstationarity
component, then an ARIMA model is used to forecast the series. So, in order to
check whether the stochastic process is stationary, the following conditions must
be satisfied for all values of t :

E (Yt ) = µ

(4.4)

E[(Yt − µ ) 2 ] = σ y2 = γ (0)

(4.5)

and
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E[(Yt − µ )(Yt −τ − µ )] = γ (τ ), τ = 1,2,...

(4.6)

Equations (4.4) and (4.5) define the mean and variance of the time series data,
while equation (4.6) gives the autocovariance at lag τ . A covariance stationary
stochastic process is a sequence of uncorrelated random variables with constant
mean and variance; a process of this kind is known as a white noise process that
is denoted by ε t , which is assumed normally distributed with mean 0 and a
variance of σ 2 .

The variables in a white noise sequence are uncorrelated; hence the
autocovariances at non-zero lags are all zero. Thus,

⎧σ 2 ,
E(ε t ε t −τ ) = ⎨
⎩0,

τ =0
τ ≠0

The time domain properties of a stationary stochastic process can be
summarized by plotting τ (t ) vs τ , which is known as the autocovariance
function. Standardizing autocovariances, that is, dividing through by the variance
process gives the autocorrelation function, which is written as:

ρ (τ ) =

γ (τ )
, τ = 0,1,2,...
γ (0)

(4.7)
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The back shift of a series denoted by B shifts a time series by one time unit.
The first lag is given by,

B(Yt ) = Yt −1 .

(4.8)

Applying B to equation (4.8) yields B 2 (Yt ) = B ( B(Yt )) = B(Yt −1 ) = Yt − 2 , so by
repeating this process, we find

Bτ (Yt ) = Yt−τ

for τ = 1,2,3,...

(4.9)

Autoregressive Process

An autoregressive process regresses a time variable on its own past values. An
autoregressive process of order p is written as

Yt = φ1Yt −1 + ... + φ p Yt − p + ε t , t = 1,2,..., T ,

(4.10)

so we can denote Yt ~ AR( p) . The back shift operator lags an observation back
into the past; for example, B(Yt ) = Yt −1 . As a result, we can write equation (4.10)
using the back shift operator as
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(1 − φ1 B − φ 2 B 2 − ... − φ p B p )Yt = ε t

(4.11)

Letting φ ( B) = 1 − φ1 B − φ 2 B 2 − ... − φ p B p , we can write equation (4.11) as

φ ( B)Yt = ε t

(4.12)

The simplest autoregressive (AR) model is the first order model, denoted by
AR(1). The first-order Autoregressive model is denoted by:

Yt = φYt −1 + ε t ,

t = 1,..., T .

(4.13)

Using algebraic manipulation, (4.13) can be written as

Yt − φYt −1 = ε t ⇔ (1 − φ1 B)Yt = ε t .

(4.14)

Here, we have used the polynomial operating on the time series to produce a
white noise error sequence for the AR(1) model.

The series is assumed to have started at time t = 1 , but the process is regarded
to have started in the remote past. Substituting repeatedly for lagged values of

Yt gives
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J

J −1

j =0

j =0

Yt = ∑ φ j (ε t − j + Yt − j ) = ∑ φ j ε t − j + φ J Yt − J

(4.15)

Taking the expectations of equation (4.15) and treating Yt − j as a fixed number,
we obtain

J −1

E (Yt ) = E (∑ φ j ε t − j ) + E (φ J Yt − J ) = 0 + φ J Yt − J = φ J Yt − J

(4.16)

j =0

J −1

J −1

J −1

j =0

j =0

j =0

since E (∑ φ j ε t − j ) = ∑ φ j E (ε t − j ) = ∑ φ j × 0 = 0 . As mentioned in the beginning of
this chapter, a time series is stationary if the mean and variance of the series at
any time t = j is constant.

We have shown that equation (4.14) is a representation of a polynomial operator
on the time series to produce a white noise error sequence; in fact, equation
(4.14) is a representation of an AR(1) model. We can also represent an AR(p)
process by a characteristic polynomial, φ ( x) = 1 − φ1 x − φ 2 x 2 − ... − φ p x p .

Another way of checking if a series is stationary is to see if the roots of the
characteristic equation are less than one in absolute value. For an
autoregressive function of order p , i.e. AR (p), the characteristic equation is
given by
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x p − φ1 x p −1 − ... − φ p = 0

(4.17)

Replacing x by 1 / B in equation (4.16) and multiplying by B p , we obtain a
polynomial equation:

1 − φ1 B − ... − φ p B p = 0

(4.18)

In order for AR(p) to be stationary, the roots of equation (4.17) should be less
than one in magnitude or the root of equation (4.18) should be greater than one
in magnitude.

Moving Average Processes

A moving average process of order q is written as

Yt = ε t + θ1ε t −1 + θ 2 ε t −2 + ... + θ q ε t − q , t = 1,2,..., T and ε t ~ N (0, σ 2 )

(4.19)

and is denoted by Yt ~ MA(q ) .

Let {Yt } be the MA(q) model given in equation (4.19). Then the following hold:
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E (Yt ) = 0

(4.20)

var(Yt ) = (1 + θ 12 + ... + θ q2 )σ 2

(4.21)

| k |> q,
⎧0,
⎪ q −| k |
cov(Yt , Yt + k ) = ⎨ 2
⎪σ ∑ θ iθ i +|k | , | k |≤ q,
⎩ i =0

(4.22)

Equation (4.22) can be shown as follows

cov(Yt , Yt + k ) = E (Yt Yt + k )

= E (ε t + θ1ε t −1 + θ 2 ε t − 2 + ... + θ q ε t −q )(ε t + k + θ1ε t + k −1 + θ 2 ε t + k − 2 + ... + θ q ε t + k − q )
=σ

q −| k |
2

∑θ θ
i =0

i

i +| k |

, where θ 0 = 1

The correlation at lag k is given by the following equation

q
⎧q −|k |
2
θ
θ
/
⎪ ∑ i i +|k | ∑ θ i , | k |≤ q, k ≠ 0
i =0
⎪⎪ i =1
ρ (k ) = ⎨1,
k =0
⎪0
⎪
otherwise.
⎪⎩

(4.23)
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The simplest moving average (MA) model is the first order model, denoted by
MA(1). The first-order moving average model is denoted by:

Yt = ε t + θε t −1 ,

t = 1,..., T ε t ~ N (0, σ 2 )

(4.24)

Substituting repeatedly for lagged values of Yt , equation (4.24) can be written as

Yt = θYt −1 − θ 2Yt − 2 + Λ − (−θ ) J Yt − J + ε t − (−θ ) J +1 ε t − J −1 (4.25)
J −1

= −∑ (−θ ) i Yt −i + ε t
i =1

We have seen that in order for AR (p) to be stationary, the roots of the
characteristic polynomial of equation (4.18) must be larger than one in
magnitude, whereas for MA (q), we have to consider invertability since the
autocorrelation function after lag q vanishes for MA(q); it is stationary.

Let {Yt } ~ MA(q ) , where Yt is given as equation (4.19). Then we can write
equation (4.19) as Yt = θ ( B)ε t , where θ ( B ) = 1 + θ1 B + θ 2 B 2 + ... + θ q B q with

B (ε t ) = ε t −1 . Therefore, in order for MA(q) to be invertible, the roots of the
equation θ ( B) = 0 must all lie outside the unit circle13.
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ARMA MODELS
The AR (p) and MA (q) models are combined to give an ARMA (p, q). By
combining these models, we get an ARMA(p,q) model with few unknown
parameters. It should also be noted that both AR (p) and MA (q) are special
cases, so it is legitimate to denote them by ARMA( p,0) and ARMA(0, q)
respectively. An ARMA Model is represented as:

Yt = φ1Yt −1 + φ 2Yt − 2 + Λ + φ p Yt − p + ε t + θ1ε t −1 + θ 2 ε t − 2 + Λ + θ q ε t − q
(4.26)

A time series {Yt } is said to be an ARMA(p,q) process if
(i) {Yt } is stationary
(ii) ∀t , φ ( B)Yt = θ ( B)ε t where ε t ~ N (0, σ 2 ) .

White Noise

A process that is purely random is known as white noise. Let {ε t }−∞ be a
∞

{ }

sequence of errors with mean and variance given by E{ε t } = 0 and E ε t2 = σ 2
respectively for which all the errors are uncorrelated across time, i.e.
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E{εtετ } =0

for t ≠ τ . A process satisfying these three conditions is called a white noise
process.

The characteristic polynomials are representations of Box-Jenkins models on
which

θ ( B) = 1 − θ1 B − θ 2 B 2 − Λ − θ q B q and φ ( B) = 1 − φ1 B − φ 2 B 2 − Λ − φ p B p .

The simplest autoregressive moving average model is the first order model,
denoted by ARMA(1,1) . The first-order autoregressive moving average model is
denoted by:

Yt = φ1Yt −1 + ε t − θ1ε t −1 ,

t = 1,..., T ε t ~ N (0, σ 2 )

(4.27)

Alternatively, equation (4.27) can be written as Yt (1 − φ1 B ) = ε t (1 − θ1 B) . Then

Yt − φ1Yt −1 = ε t − θ1ε t −1 ⇔ Yt − φ1 BYt = ε t − θ1 Bε t ⇔ Yt (1 − φ1 B) = ε t (1 − θ1 B) .

This is the form of an ARMA(1,1) .
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Non-Seasonal ARIMA Models

An ARIMA model is a generalization of an ARMA model on which differencing (d)
is involved. Let Z t = (1 − B) d Yt and assume that Z t is an ARMA( p, q) , i.e.

φ ( B) Z t = θ ( B)ε t . Then

φ ( B)(1 − B ) d Yt = θ ( B)ε t .

(4.28)

where

φ ( B) = 1 − φ1 B − φ 2 B 2 − Λ − φ p B p
θ ( B) = 1 − θ1 B − θ 2 B 2 − Λ − θ q B q

The process {Yt } is said to be an ARIMA( p, d , q) , autoregressive integrated
moving average model14. For instance an ARIMA(1,1,1) can be written as

(1 − φB )(1 − B )Yt = ε t − θε t −1 .

(4.29)

Since equation (4.29) has a difference of 1, then
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Z t = (1 − B)Yt = Yt − BYt = Yt − Yt −1 .

Hence, summing

t

t

i =1

i =1

∑ Z t = ∑ (Yk − Yk −1 ) = Yt − Y0 and assuming Y0 = 0 , Yt can be

derived from Z t by summing, and that is why we have the term, “integrated” in an
ARIMA model.

SEASONAL ARIMA MODELS

When a time series {Yt } exhibits a seasonal trend, then the ARIMA model will be
used to fit the model with a seasonality term, and it is written as:

φ ( B)Φ P ( B s )(1 − B) d (1 − B s ) D Yt = θ ( B )Θ Q ( B s )ε t

(4.30)

where

φ ( B) = 1 − φ1 B − φ 2 B 2 − Λ − φ p B p ,
θ ( B) = 1 − θ1 B − θ 2 B 2 − Λ − θ q B q ,
Φ p ( B s ) = 1 − Φ1 B s − Φ 2 B s − Λ − Φ p B s ,
1

P

Θ Q ( B s ) = 1 − Θ1 B s − Θ 2 B s − Λ − Θ Q B s .
1

Q

Therefore, {Yt } is denoted by ARIMA ( p, d , q) × ( P, D, Q) s . When a series {Yt } has
seasonality, then Yt is related to a series that cycles using an s time unit, in the
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past denoted by Ys . To demonstrate, let us consider a seasonal ARIMA(1,0,0) ×
(0,1,1)12 time series of {Yt } . Then substituting p = 1, q = 0, d = 0, P = 1, D = 1, Q = 12
and s = 12 in equation (4.30), we get

(1 − φB)(1 − B 12 )Yt = ε t − θε t −12

⇔ (1 − B 12 − φB + φB 13 )Yt = ε t − θε t −12
⇔ Yt − B 12 (Yt ) − φB (Yt ) + φB 13 (Yt ) = ε t − θε t −12
⇔ Yt − Yt −12 − φYt −1 + φYt −13 = ε t − θε t −12
⇔ Yt = Yt −12 + φ (Yt −1 − Yt −13 ) + ε t − θε t −12 .

Here we see that Yt depends upon Yt −12 , Yt −1 , Yt −13 and ε t −12 .

Model Validation and Holdout Sample

Model validation is an important part of the model development process28. Once
the model produced is validated, it can be used for decision making. For
example, the forecasted model can be used as a model prediction for the cost of
prescriptions. It is advisable to ask whether the model of prediction is validated
or not. In practice, no model will fully fit the data perfectly (100%); there is some
error to some extent. So in model building, our main task is to reduce the error
as much as possible. Model validation assures that the prediction and forecast
for the dataset analyzed is accurate and solves the problem being investigated.
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Once the models built are validated, we can make future predictions or forecast
for the prescription of antibiotics.

The forecasting models that we build for the prediction of the cost of antibiotics
may work well with the data to which they were fit; we also have to consider how
well the models will fit to freshly collected data. In order to solve this problem, we
validate the model built. By model validation, we mean to test the dataset on
another independent dataset and see how well the model will fit the new dataset.
The model built should work on an independent dataset which was not used for
fitting the model equations. For these reasons, we classify the dataset into
portions; one of which is used for model fitting and the other for model validation.
For this project, we will hold out 20% of the data for validation. By hold-out
samples, we mean that a portion of the data is used for model evaluation and the
rest of the data are used for model forecasting. If there is a hold-out sample, the
period of fit is different from the period of evaluation, which we call a hold-out
sample. The period of fit ends at a time point before the series of data ends, and
the remainder of the data are held out as a non-overlapping period for evaluation.
Hence, a hold-out sample is a period used to compare the forecasting accuracy
of models fit to past data.
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Model Diagnostics

In a time series model, each observation is correlated with past values, so there
is some correlation of present values with past values. An autocorrelation
function gives the primary diagnostics for a model fit. The autocorrelation
function at lag k , denoted by ACF( k ), represents the correlation of a time series
with itself lagged by k time units. For a given model, we can check whether
there is a need for differencing just by observing if the series autocorrelations at
each lag die off quickly or not. If the autocorrelation dies quickly, there is no
need for differencing.

The partial autocorrelation function, denoted by PACF( k ) measures the
correlation of a time series with itself at lag k adjusted for lags 1,2,..., k − 1 . The
partial autocorrelation function at lag k is the coefficient of the kth order
autoregressive term in an autoregressive model of order k . The partial
autocorrelation function plot has similar diagnostic properties to the
autocorrelation function plot.

The inverse autocorrelation function denoted by IACF( k ) is an inverse of the
autocorrelation function. The inverse autocorrelation function identifies model
behavior not detected by the PACF. Chatfield (1980) suggests that IACF should
replace the PACF as a model diagnostic tool15.
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When a series of data is non-stationary, we use an ARIMA model to produce a
forecast. Nonstationarity is removed by taking differencing ( Yt − Yt −1 ) for each
series and then building an ARIMA model for the differenced data. If the
differenced series of data is non-stationary, a second differencing ( Yt − Yt − 2 ) is
taken for each series, building an ARIMA model for the differenced data. The
antibiotics dataset has some missing values or zero for variables such as
Medicare and Medicaid. We want to test whether this series is white noise
residual, so it is crucial to do a white noise test.

The other model diagnostic statistics for an ARIMA model are Akaike's
information criterion (AIC) (Akaike 1974; Harvey 1981)16 and Schwarz's Bayesian
criterion (SBC) (Schwarz 1978)17. Using AIC and SBC, we will compare several
ARIMA models fit to the antibiotics dataset. We will choose a model with the
smallest information criteria. Both AIC and SBC are called information criteria.
The AIC is computed as

− 2 ln(L) + 2k

(4.31)

where L is the likelihood function and k is the number of free parameters. The
Schwarz’s Bayesian criterion (SBC) is computed as

− 2 ln(L) + ln(n)k

(4.32)
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where n is the number of residuals that can be computed for the time series.
Sometimes, Schwarz's Bayesian criterion is called the Bayesian Information
criterion (BIC).

A stationarity test is very important in time series modeling, especially when an
ARIMA model is built. Hence, we will perform a stationarity test such as the
Dickey-Fuller and Philips-Perron test.

Dickey-Fuller Test:

When a series has a unit root, the series is non-stationary and the ordinary least
squares estimator is not normally distributed. The limiting distribution of the
ordinary least squares estimator of autoregressive models for time series with a
simple unit root was studied by Dickey and Fuller (1979)18. Dickey, Hasza, and
Fuller (1984) obtained the limiting distribution for a time series with seasonal unit
roots19.

Let us consider the AR(p) model given in equation (4.10). If all of the
characteristic roots of equation (4.17) are less than unity in absolute value, then

Yt ~ AR( p) is stationary. If there is a unit root, then Yt ~ AR( p) is non-stationary
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p

and the sum of the autoregressive parameters given by

∑φ
i =1

i

in equation (4.10)

is equal to one. As a result, we will test for a unit root by using the hypothesis
p

H0:

∑ φi = 1 against H1:
i =1

p

∑φ
i =1

i

≠ 1 . The Dickey-Fuller test is used to test the null

hypothesis that the time series exhibits a lag d unit root against the alternative of
stationarity. We will use the Dickey-Fuller test to test for stationarity and
determine the order of differencing needed for the ARIMA modeling of the
antibiotics time series data.

Phillips-Perron Test

The Phillips-Perron is another test statistic for testing stationarity or unit roots. It
performs tests for zero mean and single mean in an autoregressive model. A
zero mean for an autoregressive model is given by

Yt = φYt −1 + ε t

(4.33)

and a single mean is given by

Yt = µ + φYt −1 + ε t

(4.34).

where ε t ~ serially correlated.
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We will compute the Phillips-Perron test for the null hypothesis that Yt has a unit
root against a stationary alternative. The Philips-Perron tests are similar to
Dickey Fuller tests, but Philips-Perron tests add an automatic correlation to the
Dickey Fuller test procedure to allow for autocorrelated residuals. For the
Philips-Perron test, the errors are identically and independently distributed.

Discussion

Time series data are stationary if the mean and variance of the series is constant
through time. However, in most situations, time series data are non-stationary.
In order to build model prediction, we have to use an ARIMA model. An ARIMA
model builds a model prediction for a non-stationary time series. An ARIMA
model does differencing to the series of data, until the series of data becomes
stationary; then a model for prediction is built. In most cases, we first do
differencing, but if the differenced series remains non-stationary, we repeat the
differencing until the series becomes stationary.

In statistics, we need to have a test to validate whether the selected model fits
the data well or not. For the models we build using ARIMA models, we will check
several model diagnostic statistics. As a model diagnostic, we will check
Akaike’s information criterion (AIC), Schwarz’s Bayesian criterion, stationarity

50

tests such as Dickey Fuller and Philips-Perron. Once these test statistics are
checked, we will build a model forecast for the antibiotics data set. We will also
evaluate the model built by holding 20% of the dataset. The hold-out sample is
used for model evaluation and the remaining 80% of the dataset will be used for
model development.
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Chapter 5

Heteroskedastic Models

There is an interest in forecasting not only the levels of the time series Yt , but
also its variance. The need to consider variance occurs when the series is more
volatile at some times compared to others. When the prescription of antibiotic
varies very often, the variance of the series is volatile, so we will be forecasting
not only the level of the series Yt but also the variance of the series. As a result,
we will use the generalized autoregressive conditional heteroskedasticity
(GARCH) model to forecast the prescription of antibiotics. The generalized
autoregressive conditional heteroskedasticity (GARCH) model is an extension of
the autoregressive conditional heteroskedasticity (ARCH) model. We will first
describe the model equation for ARCH; from that, we will set up the model
equation for GARCH 33.

In chapter four, we defined and explained the model equation for an
autoregressive process of order p that is denoted by AR(p). The model equation
for an AR(p) is given by
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Yt = φ1Yt −1 + φ 2Yt − 2 + ... + φ p Yt − p + ε t .

(5.1)

where ε t is white noise. Given Yt −1 , Yt − 2 ,..., Yt − p , we forecast Yt . An AR(p) is
utilized to do this task by regressing the present value of Yt on its past values.

In this project, we will consider the effect of the inflation rate on the cost of the
prescription antibiotics. When there is a volatile inflation rate, it would be
advisable to study changes in variance. As a result, the changing variance also
has significance on the estimation of the parameters of equation (5.1) that
describe the dynamic of the level of the time series variable Yt .

In chapter four, we showed that the unconditional variance of the error term is
constant; that means, E (ε t ) = 0 , while

E(ετ εt ) = 0 for t ≠ τ .

E(ετ ε t ) = σ 2

for t = τ and

However, if we consider the conditional variance of the

error term, ε t may not be constant due to the volatility of variance. As a result,
the error term could change from time to time. One remedy to control the
volatility of an error term ε t is to model the square of ε t as an autoregressive
order p denoted by AR(p). The modeling equation for the square of ε t is given
by:

ε t2 = α 1ε t2−1 + α 2 ε t2− 2 + Λ + α p ε t2− p + ω t
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(5.2)

where ω t is a white noise process for equation (5.2). The expected value of the
white noise in equation (5.2) is zero such that

E(ωτ ωt ) = 0 for t ≠ τ .

E(ωτ ωt ) = β 2

for t = τ and

We see that ε t is the error in forecasting Yt in

equation (5.1). A white noise process ε t satisfying equation (5.2) is known as an
autoregressive conditional Heteroskedastic process of order p, denoted by

ε t ~ ARCH ( p) . The conditional distribution of the square error term of a forecast
of Yt on the previous p squared forecast errors is given by:

Eˆ (ε t2 | ε t2−1 , ε t2− 2 ,...) = α 1ε t2−1 + α 2 ε t2− 2 + Λ + α p ε t2− p

(5.3)

For an ARCH model described in equation (5.2), we want to test whether the
residuals ε t from a regression model exhibit time-varying heteroskedasticity
without estimating the parameter estimates such as α 1 , α 2 ,..., α p . The ARCH(p)
process is regarded as an AR(p) process for the square of the error term in
equation (5.1). Bollerslev (1986) recommended the use of an ARIMA model for
analyzing the autocorrelations of ε t2

29

as an alternative to ARCH(p).

We can also write an ARCH(p) process in a slightly different form than equation
(5.2) as follows. Suppose that
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ε t = k t .vt

(5.4)

where {ε t } is an independent identically distributed (i.i.d.) sequence with zero
mean and variance of one; mathematically, E (vt ) = 0 and E (vt2 ) = 1 . If k t is
defined by

k t = α 1ε t2−1 + α 2 ε t2− 2 + Λ + α p ε t2− p

(5.5)

and ε t is generated by equation (5.4) and equation (5.5) then ε t ~ ARCH ( p)
process.

Generalized Autoregressive Conditional Heteroskedasticity Models

Engle (1982) introduced a model in which the variance at time t is modeled as a
linear combination of past squared residuals, which is called an autoregressive,
conditional, Heteroskedastic process (ARCH) 30. On the other hand, if the
variance model looks more like an ARMA than AR, we have a generalized
autoregressive conditional Heteroskedastic model denoted by GARCH.
Bollerslev (1986) introduced the GARCH models 29.

Although the requirement of equal means can be dealt with using differencing,
there is no way of dealing with the requirement of equal variances, called
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Homoskedasticity. On the other hand, if the variances are not equal, the series
has heteroskedasticity. The GARCH(p,q) process models the residual of a time
series regression. We now define a model for generalized ARCH as follows: let
the time series Yt be defined as

Yt = X t β + ε t

(5.6)

The residual is modeled as ε t = k t vt where

k t = δ 1 k t −1 + δ 2 k t − 2 + Λ + δ p k t − p + θ1ε t2−1 + θ 2 ε t2− 2 + Λ + θ q ε t2− q

(5.7)

Equation (5.7) is the generalized autoregressive conditional heteroskedasticity
model denoted by ε t ~ GARCH ( p, q) .

In the standard GARCH model, vt has the unit Normal density,

1

− vt2
2

e . In
2π
addition, to preserve stationarity, the following constraints are placed on the
coefficients: k > 0 , δ ≥ 0 , θ ≥ 0 , and

p

q

∑θ + ∑ δ
i

i

j
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j

< 1.

Discussion
The ARCH/GARCH models are used when the variance of the data is changing
from time to time; that is when there is volatility. From the least squares model,
we know that the expected value of the square of error terms is the same at any
given point in time. In this case, we have Homoskedasticity. On the other hand,
data on which the variances of the error terms are not equal to each other have
heteroskedasticity when the error terms are higher at some time point and
smaller at other time points. When there is heteroskedasticity in the error term,
the regression coefficients for ordinary least squares regression are unbiased,
but the standard errors and confidence intervals estimated will be too narrow,
giving incorrect precision. The problem of heteroskedasticity is corrected using
models ARCH and GARCH by modeling the variance 30.

A GARCH model is a weighted average of past squared residuals; it has a
declining weight on which recent observations are given larger weight than
distant, past observations. The GARCH models are good in predicting conditional
variances, so for the prescription of antibiotics where there is volatile variability in
the prescription of antibiotics, we will apply the GARCH model as a forecasting
tool. We will also use the Lagrange multiplier to test to determine the order of the
ARCH model appropriate for the data being analyzed. If the tests are significant
and for which we have smaller p-values through a given order, very high-order
ARCH model will be needed to model heteroskedasticity.

57

Chapter 6
Text Mining

Text mining is the discovery of new, previously unknown information by
extracting information from different written sources21. Once the information is
extracted, we link the information together to form new facts to be explored
further. We can ask what makes text mining different from web mining.

Suppose we want to search for the word, antibiotics, in www.google.com. The
information that would be displayed includes known facts about antibiotics, even
though we might not be sure about the meaning of the term. Here, we are not
finding new facts about antibiotics; the information was available from written
sources. In text mining, we are looking for new information that was not known
before. The new information that we found could be related to existing
information. Text mining finds interesting patterns from large databases. For our
database, we will use text mining to cluster the ICD-9 codes to a total of six
clusters. Once we classify the ICD-9 codes into six clusters, the antibiotics can
be compared to each other based on the probability density curve of the cost
variables; for example, the private insurance payments made.
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Definition of Text Mining

Text mining extracts the patterns from text language; on the other hand, data
mining extracts patterns from structured databases. If we want to extract some
information from a database using a data mining approach, a computer program
is written to extract the needed information. In text mining, we don’t write
computer programs, but rather, we link the information needed from the text
available. For instance, if we are looking for the word, diabetes, text mining
analysis finds information that can be linked to diabetes, such as the term,
insulin.

The Webster’s online dictionary defines text mining as the process of extracting
interesting and non-trivial information and knowledge from unstructured text22. In
text mining, we structure the input text by parsing, adding and removing some
derived linguistic features to derive patterns within the structured data so that
output can be evaluated and interpreted. The ideal situation of using text mining
is to classify and cluster the information so that a possible pattern will be
discovered.

Another important question to be addressed is how we discover useful
information from a large number of text documents. Nowadays, there has been a
fast increase in the number of text sources on the internet, and the need to
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extract important information from the text data has been growing. The question
arises as to how we extract the information available in the web to get the
information that we need. Text mining analyzes the unstructured web text data
by finding information that is not immediately visible within the web documents
using techniques from data mining, machine learning, and natural language
processing 22.

It should be noted that text mining is not an information extraction methodology
or a text summarization method. In order to classify a group of thousands of
documents into identifiable categories without the need of reading every
document, computer software is required.

Text mining is the automated or partially automated processing of text by
imposing structure upon text and extracting useful information from text24.
Clustering algorithms, such as feature map algorithms based on the selforganization map (SOM) 25, are frequently used for the purposes of text mining.
However, algorithms such as SOM group the text into clusters based on
similarity. Since we are using similarity, the textual data need to be converted to
numbers, i.e. by converting the text into phrases or words and then encoding
these phrases or words using techniques such as the Term Frequency-Inverse
Document Frequency (TF-IDF) 26.
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Text mining classifies the textual data into clusters so that meaningful information
can be retrieved. From each text, words or phrases are collected and a
classification is made based on the frequency of occurrence.

It should be noted that commonly existing words such as “a”, “is” and “of” are not
used as part of the classification; as a result, they are put in the stop word list. A
stop word list is a set of words not used in the classification26. For this project,
we used a set of words such as ‘have’, ‘is’, ‘before” as a stop word list. As an
application of text mining, let us consider physicians comments about patient
conditions. There is a clear difference from physician to physician on the amount
of text (words) written; some physicians are very brief, but others are wordy. As
a result, there is a difference when analyzing, say some clinical condition, due to
differences in the length of the wording.

In the previous paragraphs, we have talked about the use of text mining in
clustering unstructured text. The antibiotics dataset we are investigating has a
variable called ICD-9. ICD-9 is a categorical variable that contains a set of five
digits that are used to classify each disease condition. The ICD-9 codes are
used as textual content, so we have to devise a method to classify the ICD-9
codes into meaningful clusters. The antibiotics dataset has daily prescriptions for
the years 1996-2004. Analyzing each ICD-9 code would be cumbersome; as a
result, we will employ text mining to analyze and cluster the ICD-9 codes to a
reasonable number of clusters. We will use a maximum of six clusters; once the
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clusters are formed, we will use kernel density estimation to compare the
probability distributions of each antibiotic.

The next question we discuss is how to analyze text data using SAS software. At
this stage, we are considering for a given text datum how to classify it into an
optimal cluster and analyze the text data results.

Document Frequency Matrix

Text mining creates frequency counts for each word or phrase classified in a
cluster. It can be considered as statistical summaries where word frequency is
the statistical summary of interest. When analyzing text data, each word or
phrase is given a weight so that the document will be classified into groups. SAS
Enterprise Miner uses Entropy, Global Freq/IDF (GF-IDF), Inverse Doc Freq
(IDF), Normal, None, Chi-Squared, Mutual Information and Information Gain as
term weightings. Raw counts don’t provide much help in discriminating between
documents; therefore, weighing schemes are derived to separate documents into
groups or clusters.

In text mining, not all terms are important; some terms are more important
compared to others. As a consequence, term weighting are used to help
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designate the importance of the terms. Terms with the most discriminating
power are those that occur most frequently, but in only a few documents.

Transforming the Term by Document Frequency Matrix

There are two main methods to work with a parsed matrix; they are singular
value decomposition (SVD) and roll up terms. Text parsing is the preliminary
step to text mining. Text parsing groups similar documents based on the terms
used within the document, works with a frequency matrix table of terms by
documents to cluster documents, and creates a term-document frequency matrix.

The singular value decomposition for a matrix B is defined as

B = UΣ V

(6.1)

where U is the matrix of the term vector; Σ is a diagonal matrix with singular
values along the diagonal; and V is the matrix of the document vector. Both U
and V have orthonormal columns. The truncated decomposition of matrix B is
when the SVD calculates only the first K columns of U, Σ and V. Each column or
document in matrix B can be projected onto the first K columns of U, and each
row or term in matrix B can be projected onto the first K columns of V. The
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column projection of matrix B is a method used to represent each document by K
different concepts. Therefore, for any collection of documents, the SVD forms a
K-dimensional subspace that fits best to describe the data.

On the other hand, the method of Roll up Terms uses the highest term weights in
the document collection. The term document frequency matrix is the number of
roll up terms by the number of documents.

Analyzing the Text Data

Analysis of text data has three main purposes: exploratory analysis of the
collection of documents (text data), clustering of data and finding relationships
between terms. Statistical methods such as the nearest neighborhood algorithm
use distance proximity to cluster observations. In text mining, we use
hierarchical and expectation maximization to cluster the text data.

Expectation Maximization (EM) clustering considers the data as a combination of
probability functions that are normally distributed. Suppose we want to cluster
observations into two clusters, for two normally distributed populations with
unknown parameters. Since the parameters of the two normal distributions are
unknown, we use an iterative algorithm to estimate the parameters from the data.
Once the parameter estimates are obtained, an observation is assigned to
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cluster one if the density function for cluster one is larger than for cluster two at
that observation; otherwise it will be assigned to cluster two.

We have seen that ICD-9 codes are a set of five digits which are used for a
classification of a disease. ICD-9 codes are better if they are treated as text
rather than as category because the similarity between the codes can be related
to similarities in patient conditions, taking full advantage of the stemming
properties within the codes 27. In this project, we will use text mining to minimize
a large number of patient condition codes in to a set of clusters. Existing
methods, for example k-means clustering, cannot compress thousands of patient
codes into a patient severity index. The prescription of antibiotic dataset has
multiple prescriptions for a single patient ID; as a result more than one ICD-9
code is assigned to both patients and to antibiotics.

We will use text mining and clustering to group similar patients together so that a
meaningful analysis can be performed. For example, we can study the
difference in private insurance payments for antibiotic between the clusters, and
a comparison can be made for analysis. Once again, we will use text mining to
process and analyze the ICD-9 codes. For each patient for which antibiotic was
prescribed, all the codes associated with multiple illnesses are combined into one
text string.
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For instance, when an antibiotic is prescribed for a patient, the physician who
prescribes the antibiotic assigns the cause of the illness, which in turn defines a
diagnosis code that is assigned to the patient. On another visit, the same patient
might have a different prescription of antibiotic with the same ID and a different
diagnosis code. What text mining does is to link all ICD-9 codes for the patient
into one text string.

In this project, we will use text mining to reduce a large number of patient
condition codes, which are denoted by ICD-9 codes. The ICD-9 codes are very
large in number (in thousands). It is unrealistic to analyze each ICD-9 code, but
by classifying them into reasonable clusters, we can study the probability
distributions of each antibiotic on a variable of interest (for example, private
insurance payments). For this project, we will classify the ICD-9 codes into six
clusters to examine the relationship between different variables of interest; for
example, total payment, private insurance payment, quantity of antibiotic, number
of prescriptions, Medicare payment, and Medicaid payment.

Since there is more than one transaction per given day for a patient, many ICD-9
codes are assigned to the patient severity condition. It is impractical to analyze
each ICD-9 code; as a result, classifying the ICD-9 codes into a reasonable
cluster simplifies the analysis. We will use text mining to process and analyze
the ICD-9 codes. For each prescription, all ICD-9 codes relating to multiple
severity conditions are combined into one text string.
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Discussion
For each prescription, there is a classification of disease, on which the ICD-9
code is used to denote the condition of the disease. As the number of
prescriptions increases, the number of ICD-9 codes increases as well. Hence,
classifying and studying each ICD-9 code for each transaction becomes
cumbersome. We use clustering to define a small number of groups of
documents so that documents within any one group are related and documents
in different groups are not closely related.

The clustering algorithm uses a distance measure to classify observations in the
same cluster; in most cases, the raw data are numerical. In contrast, text mining
creates groups by looking at terms within each document. Documents or text
within a group are represented by a list of terms, and those terms will appear in
most of the documents within the group; a cluster is defined 27. Once the
observations or terms are classified into groups or clusters, a name will be
assigned as a label that best describes the contents of the cluster or group.
Domain knowledge is important when labeling a cluster, and as a result, we
consult a pharmacist to get more information.
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Chapter 7
ANTIBIOTICS RESULTS
We begin with exponential smoothing model building to forecast the prescription
of antibiotics for dataset. As discussed in chapter 3, exponential smoothing
models are characterized by giving heavier weights to recent events and lower
weights to past events. Before we build a model for the prescription of
antibiotics, we set the fit period and evaluation period. The fit period is the period
on which the model fits the data; while the evaluation period is the period where
we evaluate the model we built. We used a hold out sample of 20% of the total
data set. By hold out sample, we mean we use 80% of the data to build a model
and we use the remaining 20% to forecast for future values. For a better fit, it is
better if a hold out sample is chosen.

As an example, we will build a model fit for the antibiotic, Amoxicillin. The private
insurance payments made for the prescription of Amoxicillin will be forecast.
Here, we are building a time series model to study the prescription practice of
Amoxicillin. Plotting the forecasted private insurance payments vs. time gives
the structure of the data, and gives a clue as to what kind of model might be
appropriate for the dataset. The plot of private insurance payments vs. time
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(Figure 7.4) shows how the series data grow or decay exponentially with a
seasonal nature; as a result, we used exponential models. As discussed in
chapter 3, there are several exponential smoothing models, so the question
becomes which exponential model to fit. We used a simple exponential
smoothing model, double (brown) exponential smoothing model, linear (holt)
exponential smoothing model and damped trend linear exponential smoothing
model.

We fitted several models and we chose the model with smallest root mean
square error (RMSE) as a model of prediction. Statistically speaking, the model
with the smallest error is considered the best. We begin the analysis of the
private insurance payment with Amoxicillin. The prediction error plots for private
insurance payments made for Amoxicillin are given in figure 7.1, while figure 7.2
describes the autocorrelation plots (autocorrelation, partial autocorrelation and
inverse autocorrelation). Figure 7.3 describes a white noise plot and figure 7.4
describes the forecast plot.
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Figure 7.1 Prediction error Plots: Private Insurance Payment

The residuals don’t appear to be white noise, with visual evidence of higher
variability at the beginning of the time range. Figure 7.1 is the residual error plot
for private insurance payments for the antibiotic, Amoxicillin.

The autocorrelation plot, figure 7.2, is within the bounds of 2 standard deviation
errors, an indication that the residuals are white noise. The partial
autocorrelation plots also reveal that the correlations are within 2 standard errors;
an indication that the residuals are white noise.

70

Figure 7.2 Prediction Error Autocorrelation Plots: Private Insurance Payments

We did also check white noise, unit root test and seasonal unit root tests that are
given in figure 7.3. The white noise test indicates failure to reject a null
hypothesis of white noise for alternative lags up to 24. The unit root tests
indicate a rejection of a null hypothesis of a unit root for all polynomials up to lag
5, and the seasonal root tests indicate rejection of a null hypothesis of a seasonal
unit root up to lag 5.
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Figure 7.3 Prediction Error White Noise: Private Insurance Payments

We chose the best model for the private insurance payment made for the
antibiotic, Amoxicillin, based on the smallest root mean square error (RMSE).
We fitted an exponential smoothing model, a simple exponential smoothing
model, double (brown) exponential smoothing model, linear (holt) exponential
smoothing model and damped trend exponential smoothing model. From table
7.1, we selected the best model of fit for the private insurance payments made
for the antibiotic, Amoxicillin.
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We can see that the seasonal exponential smoothing model is selected as a
model of forecast, with the smallest RMSE. The seasonal exponential smoothing
model has also the smallest mean square error (MSE), mean absolute percent
error (MAPE), mean absolute error (MAE) and largest Pearson correlation (R2)
time series.

Time series model

MSE

RMSE

MAPE

MAE

R2

Seasonal exponential

6831

82.649

32.19

59.679

0.508

8344.5

91.348

34.519

72.565

0.284

10797.5

103.911

35.754

76.145

0.073

8338.7

91.316

34.388

72.597

0.284

8599.2

92.732

34.664

73.141

0.262

Winters additive model

6898.6

83.058

32.513

68.925

0.408

Winters multiplicative model

12111.1

110.051

32.484

74.254

-0.040

smoothing model
Simple exponential
smoothing model
Double(brown) exponential
smoothing model
Linear Holt exponential
smoothing model
Damped trend exponential
smoothing model

Table 7.1 Exponential models and Statistics of Fit
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Even though we used the RMSE for model selection in table 7.1, it is advisable to
use MAPE for error interpretation since the RMSE value tends to be larger when
compared to the MAPE. The MAPE in table 7.1 indicates that many cases have
a percent error less than 32%.

The model estimate parameter of private insurance payment for the antibiotic,
Amoxicillin is given in table 7.2.

Model Parameter

Estimates

Std. Error

T

Prob>|T|

LEVEL Smoothing weight

0.4230

0.0661

6.3971

<0.001

Seasonal Smoothing Weight

0.0010

0.1107

0.0090

0.9928

Residual Variance

7826

Smoothed Level

339.3064

Smoothed Seasonal Factor 1

205.1266

Smoothed Seasonal Factor 2

99.9419

Smoothed Seasonal Factor 3

106.0882

Smoothed Seasonal Factor 4

-17.9435

Smoothed Seasonal Factor 5

-67.4995

Smoothed Seasonal Factor 6

-86.7825

Smoothed Seasonal Factor 7

-77.4002

Smoothed Seasonal Factor 8

-69.2203

Smoothed Seasonal Factor 9

-33.8578

Smoothed Seasonal Factor 10

-35.2863

Smoothed Seasonal Factor 11

-49.4234

Smoothed Seasonal Factor 12

26.1430

Table 7.2 Parameter Estimates of Private Insurance Payment: Amoxicillin
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The smoothed seasonal factor one is for January. The exponential smoothing
model detects a seasonal difference decrease of $105.18 (99.94191205.12659=105.18468) for February compared to January for private insurance
payments made. On the other hand, the smoothed seasonal factor eleven
indicates November; the exponential smoothing model detects a seasonal
difference increase of $75.56 (26.14302-(-49.42344)=75.566) for December
compared to November private insurance payments made.

We have shown so far that forecast values for private insurance payments of
Amoxicillin were fit by the exponential smoothing model. The seasonal
exponential model has multiple steps ahead prediction, and table 7.2 gives up to
a smoothed seasonal factor level 12; this is an indication that seasonal data
forecast over a longer time period will be more accurate than forecasts over a
short period of time. Here, we are analyzing the private insurance payments
made that were obtained by summing daily expenses paid for a period of every
month.

75

Figure 7.4 Forecast for Private Insurance Payments: Amoxicillin

The forecast plot for private insurance payments made for Amoxicillin shows
seasonality with a period of approximately 12 months, which supports the model
chosen. Figure 7.4 reveals that predicted and actual private insurance payments
are very close to each other, making the residual term very small.

The predicted plot for private insurance payment for the antibiotic, Amoxicillin,
also indicates that the values are higher around January and lower around June;
this event repeats at approximately 12 months. We observe that the predicted
series is very close to the actual series, which is an indication that the model that
we built fits the data well. We have used the historical data to build what the
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private insurance payment will be in the future. One has to be cautious in
forecasting for a longer period; in the future, the forecast might not be as
accurate as we expect. For this reason, we forecast what the private insurance
payments might be for the next two years, i.e. for the years 2005-2006.

We have also investigated on average how much patients are spending on
prescriptions. At this time, we predict the total payments made on antibiotics
instead of private insurance payments made.

Figure 7.5 Prediction Error Plots: Total Payments: Amoxicillin
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The residuals do not appear to be white noise, with visual evidence of higher
variability at the middle and at the end of the time range. Figure 7.5 is the
residual error for total insurance payment for the antibiotic, Amoxicillin.

The autocorrelation plot, figure 7.6, is within the bounds of 2 standard deviation
errors, an indication that the residuals are white noise. The partial
autocorrelation plots also reveal that the correlations are within 2 standard errors;
an indication that the residuals are white noise.

Figure 7.6 Prediction Error Autocorrelation Plots: Total Payments
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We also checked white noise, unit root test and seasonal unit root tests, which
are given in figure 7.7. The white noise test indicates failure to reject a null
hypothesis of white noise for alternative lags up to 24. The unit root tests
indicate a rejection of a null hypothesis of a unit root for all polynomials up to lag
4, and the seasonal root tests indicate rejection of a null hypothesis of a seasonal
unit root up to lag 5.

Figure 7.7 Prediction Error White Noise: Total Payments: Amoxicillin

We chose the best model for the total payment made for the antibiotic,
Amoxicillin, based on the smallest root mean square error (RMSE). It should be
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noted that here we are investigating how much patients on average are paying
for the antibiotic, Amoxicillin. We fitted a seasonal exponential smoothing model,
simple exponential smoothing model, double (brown) exponential smoothing
model, linear (holt) exponential smoothing model and damped trend exponential
smoothing model. From table 7.3, we selected the best model of fit for the total
payments made for the antibiotic, Amoxicillin. We can see that the damped trend
exponential smoothing model is selected as a model forecast, with the smallest
RMSE. The damped trend exponential smoothing model has also the smallest
mean square error (MSE), mean absolute percent error (MAPE), mean absolute
error (MAE) and largest Pearson correlation (R2) time series.
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Time series model

MSE

RMSE

MAPE

MAE

R2

simple exponential

0.4943

0.7031

27.4015

0.5496

-0.094

0.5244

0.7242

28.2752

0.5817

-0.160

0.5145

0.7173

28.4545

0.5672

-0.138

0.4968

0.7049

27.8328

0.5549

-0.099

0.4943

0.7030

27.4014

0.5495

-0.094

Winters additive model

0.5207

0.72163

28.84722

0.5726

-0.152

Winters multiplicative

0.5257

0.72506

29.10547

0.5694

-0.163

smoothing model
Double(brown) exponential
smoothing model
Seasonal exponential
model
Linear Holt exponential
smoothing model
Damped trend exponential
smoothing model

model

Table 7.3 Exponential models and Statistics of fit

Even though we used RMSE for model selection in table 7.3 as mentioned in the
previous paragraph, it is advisable to use MAPE for error interpretation because
the RMSE value tends to be larger when compared to the MAPE. The MAPE in
table 7.3 indicates that many cases have a percent error less than 27%. The
model estimate parameter of total payment for the antibiotic Amoxicillin is given
in table 7.4.
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Model Parameter

Estimate

Std. Error

T

Prob >|T|

Level smoothing weight

0.24354

0.0722

3.3717

0.0019

Trend smoothing weight

0.07557

0.1038

0.7280

0.4717

Damping smoothing

0.99106

0.1746

5.56775

<0.001

weight
Residual variance

0.81101

Smoothed level

12.12410

Smoothed trend

0.12634

Table 7.4 Parameter Estimates of Total Payment on Average: Amoxicillin

The t-test p-value in table 7.4 may be questionable due to the fact that the trend
smoothing weight falls on the boundary of zero estimation bounds.
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Figure 7.8 Forecast for Total Payments: Amoxicillin

The forecast plot for total payments made for Amoxicillin shows a slightly
increasing trend from January, 2001 up to June, 2002 with damping seasonality.
Figure 7.8 reveals that predicted and actual total payments made are very close
to each other, making the residual term very small.

The predicted plot for total payment for the antibiotic, Amoxicillin, also indicates
that the values are higher around January and lower around June; this event
repeats at approximately 6 months. We also observe that the predicted series is
very close to the actual series, which is an indication that the model is a good fit.
We used the historical data to build what the total payment will be in the future.
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Erythromycin Results

In this section of the analysis, we will talk about autoregressive models (AR),
moving average models (MA), autoregressive moving average models (ARMA)
and autoregressive integrated moving average models (ARIMA). We will build
models for the antibiotic, Erythromycin, prescription. We use this example in
contrast to the use of Amoxicillin in the previous section because the optimal
model is ARIMA in contrast to exponential smoothing.

In chapter four, we have seen that an autoregressive process of order p is a
linear function of p past values plus an error term. We have shown in the
previous section that if an autoregressive model doesn’t have a constant mean
and variance through the sequence of time, there is a need for differencing.

As a result, an autoregressive integrated moving average (ARIMA) model is
introduced to solve the problem of non stationarity. What an ARIMA model does
is to take the difference of the series of data to make the series stationary.
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As a start for the analysis of the antibiotic, Erythromycin, we plotted the total
payment against the start date of antibiotics; this plot is given in figure 7.9. We
will fit an autoregressive model of order p, i.e., AR(p). Based on the smallest
MAPE, we will select p. As a result, the AR(p) model that fits the data well will be
selected. We will analyze the fit of the data by checking autocorrelation plots,
white noise and stationarity test, and the forecasted plot.
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Figure 7.9 Plot of Total Payments vs. start date: Erythromycin
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JAN2005

Figure 7.9 differs from that of figure 7.4 for Amoxicillin in the previous section in
that there is variability in the payments made from January, 1997 through
January, 1998, but for the case of Amoxicillin there is seasonal variability with
exponential increasing in the payments made.

We first investigated whether the series of data is generated from a white noise;
to do this, we plotted the total payments made versus the start date of antibiotic,
given in figure 7.9. Visual inspection shows the series is not generated from
white noise, but visual inspection is not enough to conclude whether the series is
generated from a white noise or not. As a result, we will check the residual plot,
autocorrelation plot, white noise stationarity test and see how the model built fits
the data.
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Figure 7.10 Prediction Error Plots: Total Payments: Erythromycin

The residual plot given in figure 7.10 does not appear to be white noise, even
though there is some variability at the beginning of the series. Figure 7.10 is the
residual error for total payments made for the antibiotic, Erythromycin. Figure
7.10 differs from that of figure 7.5 in the previous section in that the residual is
smaller and less variable in the distribution of the error terms.

The autocorrelation plot, figure 7.11, is within the bounds of 2 standard deviation
errors, an indication that the residuals are white noise, even though at lag twelve,
the inverse autocorrelation is non-significant; that is, outside the bound of 2
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standard deviation errors. The partial autocorrelation plots also reveal that the
correlations are within 2 standard errors; an indication that the residuals are
white noise.

Figure 7.11 Prediction error Autocorrelation Plots: Total Payments

Figure 7.11 differs from that of figure 7.6 for Amoxicillin in the previous section
since all lags are not significant while the inverse autocorrelation function value
at lag 12 is marginally significant.

We also checked white noise, unit root test and seasonal unit root tests, which
are given in figure 7.12. The white noise test indicates failure to reject a null
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hypothesis of white noise for alternative lags up to 24. The unit root tests
indicate a rejection of a null hypothesis of a unit root for all polynomials up to lag
5, and the seasonal root tests indicate rejection of a null hypothesis of a seasonal
unit root up to lag 5.

Figure 7.12 Prediction error White Noise: Total Payments: Erythromycin

Figure 7.12 differs from that of figure 7.7 for Amoxicillin in that the unit root tests
indicate a rejection of a null hypothesis of a unit root for all polynomials up to lag
5 while in figure 7.7, the unit root tests indicates a rejection of a null hypothesis of
a unit root for all polynomials up to lag 4.
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We chose the best model for the total payment made for the antibiotic,
Erythromycin, based on the smallest root mean square error (RMSE). It should
be noted that here we are investigating how much patients are paying in total for
the antibiotic, Erythromycin. The autoregressive order two, AR(2) was a perfect
fit for the data and the parameter estimates of the model are given in table 7.5.
We can see that the AR(2) model is selected as a model of forecast, with the
smallest RMSE. The MAPE in table 7.5 indicates that many cases have a
percent error less than 27%.

Time series MSE

RMSE

MAPE

MAE

R2

AIC

SBIC

model
AR(1)

6487.7

80.546

28.985

59.98

-0.738 317.996

319.579

AR(2)

6075

77.942

27.45

57.758

-0.627 317.629

320.797

AR(3)

6694.1

81.817

32.856

63.131

-0.793 325.123

331.457

AR(4)

7152.7

84.574

33.784

65.089

-0.916 327.509

333.843

AR(5)

6505.7

80.658

34.765

61.600

-0.743 326.096

334.013

Table 7.5 Autoregressive models and Statistics of fit

We have mentioned in the analysis of the antibiotic, Amoxicillin, that the RMSE
was very large when compared to the MAPE; but for the antibiotic, Erythromycin,
the RMSE value is not that big as we can see from table 7.5. For error
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interpretation, the MAPE is better, and from table 7.5, the MAPE indicates that
many cases have a percent error less than 27%. The model estimate parameter
of total payment for the antibiotic, Erythromycin is given in table 7.6.

Model Parameter

Estimate

Std. Error

T

Prob >|T|

Autoregressive, Lag 1

0.8536

0.118

7.213

<.0001

Autoregressive, Lag 2

0.0629

0.118

0.531

0.598

Model Variance

15839

Table 7.6 Parameter Estimates of Total Payment: Erythromycin

Even though the parameter estimate for autoregressive lag 2 in table 7.6 is nonsignificant, an autoregressive model of order 2, AR(2) was perfectly fit to the
data.
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Figure 7.13 Forecast for Total Payments: Erythromycin

The forecast plot for total payments made for Erythromycin shows a slightly
decreasing trend starting January, 1998 and peaks starting January, 2005. In
contrast, the forecast for Amoxicillin shown in figure 7.8 is exponentially
increasing through the range of time. Figure 7.13 reveals that predicted and
actual total payments made are very close to each other; except for values
between June, 1997 and January, 1998; there is a small difference between the
actual and forecasted values.
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The predicted plot for total payment for the antibiotic, Erythromycin, also
indicates that the values are higher around January and lower around June; this
event repeats at approximately 6 months, and is similar to that for Amoxicillin.
We also observe that the predicted series is very close to the actual series, which
is an indication that the model is a good fit. So far from our analysis examples,
the cost analysis of antibiotics has a seasonal nature. By seasonal nature, we
mean that an event happens repeatedly; for example, if the event happens every
six months, we say it has six-month seasonality.

High Performance Forecasting

In this section of the chapter, we will use the High Performance Forecasting
procedure to forecast prescriptions of antibiotics. The High Performance
Forecasting analyzes time series (observations that are equally spaced at a
specific time interval, for our case, month), or transactional data (observations
that are not equally spaced with respect to a particular time interval as in our
original antibiotic dataset). We will also plot the forecast series for several
antibiotics in the same plot; in that case, comparisons can be made very easily.
The historical series and forecasted series for several antibiotics can be drawn in
the same plot, so that comparisons can be made and further studies can be
performed on the nature of the trend of the forecast. In this section, we will
identify and forecast series components such as the actual, predicted, lower
confidence interval, upper confidence limit, prediction error, trend, seasonality
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and error (irregular). Trend usually refers to a deterministic function of time,
which means the deterministic component exhibits no random variation and can
be forecast perfectly, while a stochastic component is subject to random variation
and can never be predicted perfectly except for chance occurrence.

Seasonality refers to the repetitive behavior at known seasonal periods, for
instance, six months for antibiotics prescription. The High Performance
Forecasting splits the current value of observation into trend, seasonal and error
Components. In contrast to the previous section on time series forecasting, high
performance forecasting can be used to forecast several variables by group,
determines the best model from a list of models using the technique HPF
DIAGNOSE and HPF ENGINE and can be used to forecast for a database with a
large number of observations.

In this analysis section of the dissertation, we will use the antibiotic, Cipro, as an
example to show and forecast the variables of interest (such as total payment,
private insurance payment, quantity, amount of prescription, Medicare and
Medicaid). As mentioned in chapter two, the data analysis section, we have
created an antibiotics dataset by concatenating each antibiotic. Cipro is a
commonly prescribed antibiotic, and the dataset we have shows a tremendous
number of observations. Figure 7.14 gives the plot of total payment, private
insurance payment, Medicare payment and Medicare against the start date of
antibiotic. From this plot, we can visually inspect how much difference really
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occurs between total payment, private insurance payment, Medicare payment
and Medicare payments and give ideas as to what to expect when we make the
forecast for these variables. We have used SAS CODE 7 to create the Cipro
dataset and plot the figure 7.14.
Data cipro; set diser.disertation;
where RXNAME IN ('CIPRO');
RUN;
PROC SORT DATA=cipro;
by RXNAME STARTMEDDATE;
run;
Proc hpf data=cipro out=cipro lead=0;
id startmeddate interval=month accumulate=total;
forecast RXMDX RXMRX RXPVX RXXPX /model=none;
run;
title1 'Cipro Variables';
axis2 label=(a=-90 r=90 "PAYMENT");
SYMBOL1 INTERPOL=JOIN HEIGHT=10pt VALUE=NONE
LINE=1 WIDTH=2;
SYMBOL2 INTERPOL=JOIN HEIGHT=10pt VALUE=NONE
LINE=1 WIDTH=2;
SYMBOL3 INTERPOL=JOIN HEIGHT=10pt VALUE=NONE
LINE=1 WIDTH=2;
SYMBOL4 INTERPOL=JOIN HEIGHT=10pt VALUE=NONE
LINE=1 WIDTH=2;
Legend1 FRAME;
Axis1 STYLE=1 WIDTH=1 MINOR=NONE;

CV=BLUE
CV=GREEN
CV=RED
CV=CYAN

PROC GPLOT DATA=CIPRO;
PLOT RXMDX*STARTMEDDATE RXMRX*STARTMEDDATE
RXPVX*STARTMEDDATE
RXXPX*STARTMEDDATE /OVERLAY HAXIS=AXIS1
VAXIS=AXIS2
HAXIS='01JAN1996'D TO '01JAN2005'D BY YEAR
FRAME LEGEND=LEGEND1;
RUN;
SAS CODE 7

Table 7.7 SAS codes for model forecasting and plotting: Cipro

95

Figure 7.14 Cipro variables plot vs. Start Date of Antibiotics

We have used SAS CODE 7 to accumulate the daily observations into an
accumulated sum of monthly values, and then plotted each variable of interest
(Medicaid, Medicare, Private Insurance and Total Payment) against the start
antibiotic date. Figure 7.14 gives a starting point to see the relationships
between these variables, and we can easily see that the Total Payment made
surpasses Medicaid, Medicare and Private Insurance payments. On the other
hand, the Medicare payment made for Cipro is smaller when compared to the
Medicaid for almost every time point. As we can see from figure 7.14, the plot for
insurance payment fluctuates randomly; this might indicate that the data for Cipro
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is non stationary. As a result, an ARIMA model is one of the choices as a model
prediction.

Also from figure 7.14, we can see that between April, 2002 and July, 2002, there
is a sudden increase in the insurance payment made for Cipro. We can think of
this as level shift or an event that happened at that moment of time that makes
the increase, or that particular observation could just be an outlier. The model
that we will build automatically detects whether a particular observation is an
outlier or not. The dataset, Cipro, has 1674 daily observations obtained from the
means procedure given in table 7.8. Cipro is a commonly prescribed antibiotic,
and we have a reasonable number of observations for model building and
forecasting; as a result, we will use it as an example to build a model for
prediction. The Proc Means SAS procedure given in SAS CODE 8 was used to
analyze the distribution of the observations. Once we have an idea how the
observations are linked, we can select a model based on the number of
observations, maximum, minimum and standard deviation of the antibiotics
dataset.
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The MEANS Procedure
Analysis Variable: RXPVX = PRIVATE INSURANCE
ANTIBIOTICS NAME

N Obs

Sum

Minimum

Maximum

STDV

AMOXICILLIN

20457

44292.52

0.00

111.88

4.61

AMPICILLIN

1038

1693.86

0.00

54.60

3.52

AZITHROMYCIN

377

1985.20

0.00

262.27

18.45

CEFACLOR

597

14392.84

0.00

187.05

30.07

CEFADROXIL

239

5741.64

0.00

181.00

28.61

CEFUROXIME

28

2039.83

0.00

156.80

41.52

CEPHALEXIN

4788

41841.26

0.00

124.10

13.69

CIPRO

1674

53009.37

0.00

323.45

44.45

CLARITHROMYCIN

156

4785.03

0.00

87.38

35.39

CLINDAMYCIN

403

4597.68

0.00

123.40

16.53

CLOTRIMAZOLE

647

2210.43

0.00

142.11

14.63

DICLOXACILLIN

487

1277.08

0.00

49.24

8.06

DOXYCYCLINE

1054

8482.74

0.00

121.12

14.96

ERYTHROMYCIN

2226

5077.73

0.00

62.16

5.60

KEFLEX

1490

27802.95

0.00

115.78

29.37

SULFAMETHOXAZOLE

113

561.46

0.00

19.00

8.10

TEQUIN

408

11831.47

0.00

174.75

33.81

TETRACYCLINE

477

1395.82

0.00

97.48

10.21

TOBRAMYCIN

839

4003.18

0.00

44.69

5.16

VANCOMYCIN

73

703.34

0.00

262.60

34.17

Table 7.8. The means procedure for Private Insurance
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Proc means data=Diser.Disertation sum nway min
max std maxdec=2;
class RXNAME;
VAR RXPVX;
RUN;

SAS CODE 8
Table 7.9 SAS code for the Means procedure

From the means procedure given in table 7.8, we selected the antibiotic, Cipro, to
investigate the private insurance payments made. As the main purpose of this
dissertation is to build model forecasts for antibiotics, building model forecasts for
Cipro’s private insurance payment would be an ideal situation.

We will first build several models using the Proc hpfdiagnose statement shown in
SAS CODE 9, and put the models into the model repository (warehouse). We
then utilize the models built in hpfdiagnose to the dataset using hpfengine.
These methods select the best model using the criterion specified; for our case,
we selected RMSE as an error of model selection. The model repository is a
collection of a set of models to use to forecast the antibiotic, Cipro. The
HPFDIAGNOSE procedure builds a model based on MODELREPOSITORY, and
models specified such as ARIMAX (autoregressive moving integrated moving
average model), ESM (exponential smoothing model) and UCM (unobserved
components model). The HPFENGINE procedure selects the models based on
the smallest RMSE, and plots several graphs such as forecast, residual,
autocorrelation plot etc.
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We have built a model to forecast the private insurance payment made for the
antibiotic, CIPRO. The parameter estimates given in table 7.9 indicate that there
is an outlier on September, 2002; we have visually estimated the range of points
where an outlier might happen as discussed previously. The plot of private
insurance payments vs. start antibiotic date given in figure 7 14 gives a starting
point to show how the data behave through time. We can see that there is
fluctuation of the data points across different time points, which we suspect
indicates non-stationarity. For this reason, an ARIMA model would be a typical
model of choice. We built a predictive model using the SAS CODE 9 for private
insurance payments made for the antibiotic, Cipro.

Parameter Estimates
Component

Parameter

Estimate

Standard Error

t Value

Approx
Pr > |t|

RXPVX

AR1_1

-0.52158

0.09584

-5.44

<.0001

RXPVX

AR1_2

-0.26791

0.09718

-2.76

0.0069

AO01SEP2002D

SCALE

1700.4

351.03913

4.84

<.0001

Table 7.10 Parameter Estimates of Private Insurance Payment: Cipro

The component in the parameter estimate given in table 7.10 suggests that the
event in September, 2002 resulted in an increase of $1700.40 in the payment of
private insurance for the antibiotic, Cipro. We also have significant AR(1) and
AR(2) parameters that indicate the model is well built. The parameter, AR1_1, of
the component, RXPVX (Private Insurance payment), represents an
autoregressive process of order 1 with a difference of one, while AR1_2 is an
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autoregressive process of order 2 of difference one. The parameter,
AO01SEP2002D, represents an additive outlier at September, 2002 and the
scale indicates that the increase occurred due to the additive outlier.
PROC HPFDIAGNOSE DATA=CIPRO
OUTEST=CIPROSTATE CRITERION=RMSE
BASENAME= AMXESM PRINT=SHORT
MODELREPOSITORY=SASUSER.ANTIBIOTICSMODELS;
ID STARTMEDDATE INTERVAL=MONTH;
FORECAST RXPVX ;
ARIMAX PERROR=(12:24) P=(0:12) Q=(0:12) CRITERION=SBC
METHOD=MINIC;
ESM; UCM;
RUN ;ODS RTF;
ODS GRAPHICS ON;
PROC HPFENGINE DATA=CIPRO
MODELREPOSITORY=SASUSER.ANTIBIOTICSMODELS
INEST=CIPROSTATE
GLOBALSELECTION=TSSELECT
PRINT=(SELECT ESTIMATES) LEAD=24
OUTFOR=CIPROTOTAL
OUTEST=CIPROTEST
OUTSTAT=CIPROSTAT PLOT=ALL;
FORECAST RXPVX;
ID STARTMEDDATE INTERVAL=MONTH;
RUN;
ODS RTF CLOSE;
ODS GRAPHICS OFF;

SAS CODE 9

Table 7.11 SAS code for building Private Insurance model for Cipro
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The HPFDIAGNOSE procedure builds models from the selected list (ARIMAX,
ESM and UCM); the MODELREPOSITORY is a warehouse for the model built
and the model estimates are put in the OUTEST=dataset. The HPFENGINE
procedure builds the best model from the MODELREPOSITORY, which also
uses some models from GLOBALSELECTION= where the new models built are
stored in MODELREPOSITORY=SASUSER.ANTIBIOTICS. The statements,
OUTFOR= OUTEST= and OUTSTAT=, put the values of the forecast, estimates
and statistics respectively in a dataset.

The PERROR= specifies the range of the AR order for obtaining the series,
P=specifies the AR order, Q= specifies the range of the MA order,
CRITERION=SBC specifies that Swartz Bayesian Criterion is selected and the
METHOD=MINIC specifies Minimum Information Criterion is selected. We have
selected the best model for Cipro private insurance payment from the listed
models in SAS CODE 9. The SAS CODE 9 selects the best model of forecast
based on the smallest RMSE, and from table 7.12, we see that an ARIMA model
with autoregressive order two and difference of one is chosen as the predictive
model. The model AMXESM50, AMXESM 51 and AMXESM 52 are the models
that were selected from the list of models in the model repository.
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Model Selection Criterion = RMSE
Model

Statistic

Selected

Label

AMXESM50

398.24401

Yes

ARIMA: RXPVX ~ P = (1,2) D = (1) NOINT

AMXESM51

428.92004

No

Simple Exponential Smoothing

AMXESM52

511.79995

No

UCM: RXPVX = LEVEL + ERROR

Table 7.12 Model selection Private Insurance Payment: Cipro

We have also investigated the prediction error for the normal curve and kernel
density estimation for private insurance payments. Figure 7.14 reveals that the
normal curve fitting is closer to the kernel density estimation (for unknown
distribution). The occurrence of the outlier on September, 2002 caused the gap
between the two fits.

Figure 7.15 Prediction error for Insurance Payment
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We have also investigated the prediction error for autocorrelation plot, partial
autocorrelation plot and inverse autocorrelation plot. Each observation in a time
series is correlated with previous prescriptions made, so it is important to analyze
the autocorrelation function plots.

Figure 7.16. ACF plot of Private Insurance payment of Cipro
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Figure 7.17 PACF plot of Private Insurance payment of Cipro

The error prediction for the autocorrelation function (figure 7.16) and partial
autocorrelation function (figure 7.17) for the ARIMA model built shows that the
correlations are within the bound of two standard errors; this reveals that the
models are fitting the data well. As a consequence, we might adopt the ARIMA
model as a model forecasting for the private insurance payment of the antibiotic,
Cipro. The autocorrelation function plot and partial autocorrelation plot are also
associated with the forecast model plot. The more the lags are outside the
bounds of confidence, the more the model and forecast diverge. We also
investigated the predictive model for private insurance payments for Cipro.
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Figure 7.18 Model and Forecast for Private Insurance Payment of Cipro

The points in figure 7.18 represent the monthly private insurance payments for
the antibiotic, Cipro and the thick blue line is the predictive model that we built.
Most of the observations, with very few exceptions, lie within the 95% confidence
band. There is a fairly constant increase in Private Insurance payments until the
middle of January, 2001; then there is a sudden increase in September, 2002.
As mentioned earlier, in time series forecasting, we use the historical data to
predict or forecast what tomorrow’s value will be based on today’s value.

The fact of the matter is that we chose to forecast for two years (year 2005 and
year 2006) to get a better fit of the data; otherwise, we could forecast for the next
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50 years and so forth. But forecasting for a very long period of range gives a
poorer fit; the reason is that there might be some other covariates that will occur
in the near future that influence the forecast method used at the present time.

Figure 7.19 Stationarity Component Private Insurance for Cipro

Figure 7.19 is the stationary component of the model that we built, and we can
see that after differencing the data, which was done by the ARIMA procedure
given in SAS CODE 9, the series is stationary.
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Figure 7.20 Y Component of Private Insurance for Cipro

Figure 7.20 is obtained by plotting each data point of the series forecast and
connecting them by a line. This plot also reveals that in September, 2002, there
is a sudden increase, which we define as an outlier. Figure 7.21 plots the outlier
or event obtained through the model that we built. Outliers or events can be
taken as single data points that we call point interventions in a time series. We
will consider the data point of September, 2002 as a single data point; in other
words, we will construct a dummy variable, and see if this can improve the
forecast plot.
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Figure 7.21 Outlier: Private Insurance for Cipro

The payments made for all the antibiotics in our dataset were calculated without
taking inflation rate as a factor. But from an economic standpoint, inflation rate is
important to consider when determining the price of items at a given period of
time. As the inflation rate increases, the price of commodities increases as well
and vice versa. Therefore, we introduced inflation rate as a dynamic regressor
and compared the model error with the one without a dynamic regressor. The
difference between regressor variable and dynamic regressor is that the latter
uses past values of the predictor series, so that it will help us to model effects
that take place gradually. We added inflation rate to the dataset of Amoxicillin
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and investigated whether considering inflation rate as a dynamic regressor
improves the model forecast.

Figure 7.22: Forecasting Plot of Cipro using Inflation as Dynamic Regressor

The new model, which includes a dynamic regressor (figure 7.22), fits the data
much better than ARIMA (2, 1, 0) without a dynamic regressor (figure 7.18). The
predicted private insurance payment for the years 2005-2006 was constantly
decreasing when a dynamic regressor was introduced. One possible reason is
that the inflation rate affects the payments made for private insurance, and also
the inflation rate was increasing through the time period. The root mean square
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error was dropped from 559 to 430, which is an indication that introducing the
dynamic regressor improved the model forecast. The plot of inflation rates from
1996-2004 is given in figure 7.23.
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Figure 7.23: Inflation Rates as a Dynamic Regressor
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01JAN2006

Heteroskedasticity and GARCH Models

In chapter five, we talked about approaches to dealing with heteroskedasticity.
The ordinary regression model is used when the errors have the same variance
throughout the time points; in such a scenario, the data are called
Homoscedastic. On the other hand, if the errors have non constant variances,
then the data are called Heteroskedastic. Erroneously using ordinary leastsquares regression for Heteroscedastic data causes the ordinary least squares
estimate to be inefficient. As a consequence, we look for models that account for
the changing variances that make efficient use of the data. On the other hand,
heteroskedasticity can make the ordinary least squares estimates forecast error
variance inaccurately, as the predicted forecast variance is based on the average
variance instead of the variability at the end of the series 33.

The weighted regression method is a good method if the error variance at
different time points is known, but if the error variance at different time points is
not known, we must estimate it from the data by modeling the changing error
variance. The generalized autoregressive conditional heteroskedasticity
(GARCH) will be used to model for the heteroskedasticity errors. The analysis of
the antibiotic, Erythromycin given in the previous section of this chapter reveals
that there is higher variability in the beginning of the series that is given in figure
7.9. A GARCH model is a weighted average of past squared residuals that has a
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declining weight on which recent observations are given larger weight than
distant, past observations. Even if the series of time points given in figure 7.9
looks Heteroskedastic, we need to test it statistically.

Ods html;
Proc autoreg data=hpfertro;
model RXXPX = STARTMEDDATE / nlag=12 archtest dwprob
noint;
output out=out out=RXXPXresid;
run;
ods html close;
SAS CODE 11

Table 7.13 SAS code test heteroskedasticity

We used SAS CODE 11 to test for heteroskedasticity, by regressing Private
Insurance payments on start mediation date and we used the ARCHTEST option
to test for Heteroscedastic ordinary least squares residuals. We used the
DWPROB option to test for autocorrelation.
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Ordinary Least Squares Estimates
SSE

4030688.02

MSE

37670

SBC

1448.12303

Regress R-Square

0.4108

Durbin-Watson

0.3475
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DFE
Root MSE

194.08756

AIC

1445.4409

Total R-Square

0.4108

Table 7.14 Ordinary Least Squares Estimates

Q and LM Tests for ARCH Disturbances
Order

Q

Pr > Q

LM

Pr > LM

1

50.0071

<.0001

48.7292

<.0001

2

77.6249

<.0001

49.1592

<.0001

3

80.8958

<.0001

56.3419

<.0001

4

81.1530

<.0001

56.4903

<.0001

5

81.3417

<.0001

59.5441

<.0001

6

82.0714

<.0001

59.5462

<.0001

7

84.4500

<.0001

59.5559

<.0001

8

88.7266

<.0001

60.2213

<.0001

9

95.2285

<.0001

60.9780

<.0001

10

96.1345

<.0001

66.4472

<.0001

11

96.4317

<.0001

66.6586

<.0001

12

97.0906

<.0001

67.2222

<.0001

Table 7.15 Q and LM Tests for ARCH Disturbances
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The Q statistic tests for changes in variance across time using lag windows
ranging from 1 through 12. The p-values for the test statistics are significant and
strongly indicate heteroskedasticity, with p < 0.0001 for all lag windows. The
Lagrange multiplier (LM) tests also indicate heteroskedasticity. Both Q statistics
and the Lagrange multiplier help to determine the order of the ARCH model
needed for modeling the heteroskedasticity, on which the changing variance is
assumed to follow an autoregressive conditional heteroskedasticity model.

Variable
STARTMEDDATE

DF

Estimate

Standard Error

t Value

Approx
Pr > |t|

1

0.0109

0.001261

8.64

<.0001

Table 7.16 Parameter Estimate

Ordinary Least Squares Estimates

The parameter estimates given in table 7.15 are also significant, an indication
that the data have a Heteroskedastic property. Once we checked for
heteroskedasticity of the data, then we used a generalized autoregressive
conditional heteroskedasticity model (GARCH) that takes care of the
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heteroskedasticity of the data. SAS CODE 12 was used to build a GARCH
model and test the parameter estimates.

ods html;
Proc autoreg data=hpfertro;
model RXXPX = STARTMEDDATE / nlag=12 garch=(q=1,p=1) maxit=500
noint;
output out=out cev=vhat;
Run;
ods html close;
SAS CODE 12
Table 7.17 SAS code to build GARCH model for Private Insurance of Cipro

SAS CODE 12 was used to build GARCH (1, 1), by going back 12 lags into the
past. This code will test how many autoregressive orders are needed for the
Heteroskedastic variable, Private insurance payments, made for the antibiotic,
Erythromycin. We fitted an AR(12) and GARCH(1,1) model for the Private
Insurance Payment series regressed on start antibiotic date. The AR(12)
specifies an autoregressive error of order 12, while GARCH(1,1) specifies a
conditional variance model. SAS CODE 12 will compute the estimated
conditional error variance at each time period in the variable VHAT (estimated
conditional error variance series) and output the dataset named OUT.
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GARCH Estimates
SSE

1263311.36

MSE

11697
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Observations

14945.1458

Uncond Var

Log Likelihood

-655.97225

Total R-Square

SBC

1382.17648

AIC

Normality Test

1918.0137

Pr > ChiSq

0.8153
1341.94451
<.0001

Table 7.18 GARCH Estimates

The normality test is significant (p < 0.0001), which is consistent with the
hypothesis that the residuals from the GARCH model,

εt
kt

, are normally

distributed. The parameter estimate is significant. The parameter estimates
given in table 7.19 include rows for the GARCH parameters. ARCH0 represents
the estimate for the parameter ω , ARCH1 represents α 1 , and GARCH1
represents δ 1 . The parameter estimates for the autoregressive errors are
significant up to lag 1; as a result, we adopt AR(1). Also, the GARCH1
parameter estimate is significant. The model for Erythromycin Private Insurance
is therefore built with AR(1) + GARCH(1,1) on which the heteroskedasticity
nature of the data is controlled. As we have discussed in the beginning of this
chapter, an AR(2) was the best model predicted with a negative correlation of
R2=-0.627.
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The autoregressive order of lag one is the only one significant, so we don’t need
lags of up to 12. The estimate of the mean term in the Hetereskedastic process
is 0.0850, which is not significant, but the estimate of coefficient of the square of
error terms 0.2103 is significant. The estimate of error variance at lag 1 is
0.7376, which is significant at a 5% level of significance.
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Variable

DF

Estimate

Standard Error

t Value

Approx
Pr > |t|

STARTMEDDATE

1

0.0185

0.005313

3.48

0.0005

AR1

1

-0.5830

0.2065

-2.82

0.0047

AR2

1

-0.3273

0.2008

-1.63

0.1030

AR3

1

0.0545

0.2386

0.23

0.8195

AR4

1

0.1816

0.2391

0.76

0.4474

AR5

1

-0.0956

0.2075

-0.46

0.6448

AR6

1

-0.0242

0.2607

-0.09

0.9260

AR7

1

-0.1437

0.2584

-0.56

0.5782

AR8

1

0.0351

0.3917

0.09

0.9286

AR9

1

0.0115

0.3367

0.03

0.9726

AR10

1

0.0312

0.2624

0.12

0.9055

AR11

1

-0.0825

0.2040

-0.40

0.6858

AR12

1

-0.004789

0.1342

-0.04

0.9715

ARCH0

1

0.0850

0.0757

1.12

0.2614

ARCH1

1

0.2103

0.0847

2.48

0.0130

GARCH1

1

0.7376

0.0960

7.68

<.0001

Table 7.19 GARCH parameter estimates

We also investigated the average Medicare and Medicaid payments made for
prescriptions of antibiotics. The term Medicaid is referred to as the amount of
support in terms of healthcare given to low income people. A family is on the
category of low income if the percentage of income of the household is less than
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15,000 35. Medicaid only consists of a very small portion of the total payment
made; that means the majority cost is paid by the patient. The government pays
only a small portion of the total payment. We have built a model of prediction for
both Medicare and Medicaid payments made for the antibiotic, Cephalexin.
Cephalexin is a commonly prescribed antibiotic. A model of forecast was built for
the Medicaid payment of Cephalexin; a double (brown) exponential smoothing
model was built. The Medicaid payment was increasing through the years 1996
up to 2004, and the forecasted Medicaid payment for the years 2005 and 2006
was increasing as well; this means the government was paying more money for
Medicaid than the previous years. One has to keep in mind that this increase in
payment is due to cost increase; insurance payments increase overall due to
total payment increase.

Figure 7.24 Model forecast for Medicaid payment: Cephalexin
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We also investigated the average Medicare payments made for the prescription
of Cephalexin. The term, Medicare, is referred to as the amount of support in
terms of healthcare given to the American elderly people age of 65 or more.
People with disabilities are also eligible for Medicare payments. Figure 7.25
indicates that on average, the government pays a maximum of less than three
dollars for the prescription of Cephalexin. The data for Medicare payment has
many missing observations, but in order to maintain the series of the data, we set
missing values to zero; that is why a mean model was built as a model of
prediction. As we can observe from figure 7.24, the model built did not capture
most of the data; the reason being that the data has two observations of zero at
November, 2004 and December, 2004. Statistically speaking, when we have as
many observations missing, it is ideal to consider the mean as a model of
prediction.
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Figure 7.25 Model forecast for Medicare payment: Cephalexin

Comparing Medicaid payment (figure 7.24) and Medicare payment (figure 7.25),
we see that Medicaid payments are three times as large as Medicare payments;
further studies can be made if the number of low income people are three times
as much as elderly or disabled people.

We finally built a model of forecast for the remaining antibiotic for the total
payment made. As we have seen earlier in this chapter using the Means
procedure, we found out that Amoxicillin was the most prescribed with 20,457
transactions while Cefuroxime was the least prescribed with only 28 transactions.
The model forecast for all antibiotics was built using SAS CODE 13.
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Proc sort data=diser.disertation;
by RXNAME STARTMEDDATE ;
RUN;
PROC HPF DATA=diser.disertation OUT=disertation LEAD=0;
ID STARTMEDDATE INTERVAL=MONTH ACCUMULATE=TOTAL;
FORECAST RXXPX RXPVX RXMDX RXMRX RXQUANTY DRUG
/MODEL=NONE;
BY RXNAME;
RUN;
Proc HPF data=disertation out=sasuser.forecast lead=24;
id startmeddate interval=month;
forecast RXXPX RXPVX RXMRX RXMDX RXQUANTY DRUG/select=mape
holdout=36;
BY RXNAME;
Run;

SAS CODE 13
Table 7.20 SAS code for all antibiotics model building

Plotting the forecasted series of the antibiotics in one plot is the best way to
compare the number of prescriptions, quantity of prescriptions and total
payments made between several antibiotics. We plotted all twenty antibiotics in
one graph, but as we can see from figure 7.26, we can hardly make
comparisons; the reason being the difference in total number of transactions
made for the antibiotics. As a result, we classified the antibiotics into classes of
three based on the number of transactions.
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Figure 7.26. Model forecast for Total payments for all antibiotics

Figure 7.26 gives the forecasted plot of all the antibiotics for total payments made
for all twenty antibiotics.
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Figure 7.27. Model forecast for Cefaclor, Cefuroxime, Clarithromycin, Clotrimazole,
Erythromycin, Keflex and Tetracycline: Total Payment

The total payments made for Keflex is rising starting in January, 2001, while the
forecast series for Clarithromycin is decreasing.
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Figure 7.28. Model forecast for Amoxicillin, Azithromycin, Cephalexin, Cipro, and
Vancomycin: Total Payment

The total payment for Vancomycin is highest on May, 2001; it is an outlier, while
Ampicillin, Cipro, Azithromycin and Cephalexin increase through time with the
forecast for Azithromycin decreasing.
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Figure 7.29. Model forecast for Ampicillin, Cefadroxil, Clindamycin, Dicloxacillin,
Doxycycline, Tequin and Tobramycin: Total Payment

The total payment for Tequin is highest in January, 2002, while Dicloxacillin is at
its peak around January, 2001.
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Figure 7.30. Model forecast for Cefaclor, Cefuroxime, Clarithromycin, Clotrimazole,
Erythromycin, Keflex and Tetracycline: Number of Prescription

The number of prescriptions of Erythromycin was higher until January, 1999, and
then the number of Keflex prescriptions surpassed the number of those for
Erythromycin.
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Figure 7.31. Model forecast for Amoxicillin, Azithromycin, Cephalexin, Cipro, and
Vancomycin: Number of Prescriptions

The number of prescriptions of Amoxicillin was greater than the number for
Azithromycin, Cephalexin, Cipro, Vancomycin, but all prescriptions were
seasonally increasing through time.
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Figure 7.32. Model forecast for Ampicillin, Cefadroxil, Clindamycin, Dicloxacillin,
Doxycycline, Tequin and Tobramycin: Number of Prescriptions

The number of prescriptions for Ampicillin, Cefadroxil, Clindamycin, Dicloxacillin,
Doxycycline, Tequin and Tobramycin are close to each other, with Dicloxacillin at
its highest value on January, 2001.
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Figure 7.33. Model forecast for Cefaclor, Cefuroxime, Clarithromycin, Clotrimazole,
Erythromycin, Keflex and Tetracycline: Quantity

The quantity of antibiotics prescribed is close for each antibiotic starting January,
1999 with a slightly higher quantity of prescriptions for Keflex around May, 2003.
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Figure 7.34. Model forecast for Amoxicillin, Azithromycin, Cephalexin, Cipro, and
Vancomycin: Quantity

Amoxicillin prescription quantity is higher compared to Cipro, Azithromycin,
Cephalexin and Vancomycin, while Cipro and Vancomycin have the smallest
quantity of prescriptions.
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Figure 7.35. Model forecast for Ampicillin, Cefadroxil, Clindamycin, Dicloxacillin,
Doxycycline, Tequin and Tobramycin: Quantity

Ampicillin prescription quantity is higher from January, 1996 up to May, 1999, but
the series of prescription quantity is about the same starting in January, 2000,
with a sudden peak for Dicloxacillin, Ampicillin and Clindamycin.

From an economic stand point, we know that the cost of an item is determined by
the market; that means that the supply and demand play a major part. By the
same token, the cost of antibiotics depends on the number of prescriptions and
the quantity of antibiotics sold. One has to test statistically whether the number
of prescriptions and the quantity of prescriptions significantly predict the total
payments made for the antibiotics. We regressed the total payment of antibiotic
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on the quantity and the number of prescriptions. We tested statistically if the
quantity and the number of antibiotics affects the total payments made on
antibiotic. We picked the antibiotic, Amoxicillin, to demonstrate the effect of
predictors (quantity and number of prescriptions) on predicting the total payment.
DATA AMOXICILLIN;
SET DISER.DISERTATION;
WHERE RXNAME IN ('AMOXICILLIN');
RUN;
PROC HPF DATA=AMOXICILLIN OUT=AMOXICILLIN LEAD=24;
ID STARTMEDDATE INTERVAL=MONTH ACCUMULATE=TOTAL;
FORECAST RXXPX/MODEL=NONE;
FORECAST RXQUANTY/MODEL=BESTS SELECT=MAPE;
FORECAST DRUG/MODEL=WINTERS TRANSFORM=LOG;
RUN;
PROC AUTOREG DATA=AMOXICILLIN;
MODEL RXXPX=RXQUANTY DRUG;
OUTPUT OUT=TOTAL P=PREDICTED;
LABEL RXQUANTY='QUANTITY';
RUN;

SAS CODE 14

Table 7.21 SAS code for regression procedure of total payment of Amoxicillin

SAS CODE 14 was used to create the dataset, Amoxicillin, using the Data
statement, with no predictive model for total payment, best seasonal model for
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quantity of antibiotics, and Winter’s model with a log transformation for the
number of prescriptions (drug).

The AUTOREG Procedure
Dependent Variable

RXXPX
TOTAL PAYMENT

Ordinary Least Squares Estimates
SSE
2513834.41
MSE
23941
SBC
1406.49748
Regress R-Square
0.9117
Durbin-Watson
0.7658

Variable

DF

Intercept
1
RXQUANTY 1
DRUG
1

Estimate
0.9126
0.0445
7.1520

DFE
Root MSE
AIC
Total R-Square

Standard
Error

t Value

34.2248
0.0167
1.2771

0.03
2.66
5.60

105
154.72970
1398.45109
0.9117

Approx
Pr > |t| Variable Label
0.9788
0.0091
<.0001

QUANTITY
NUMBER OF PRESCRIPTIONS

Table 7.22 Parameter Estimates for Predicting Total Payment

The parameter estimates for RXQUANTY and DRUG are significant with a pvalue of 0.0091 and <0.0001 at 5%. The significant parameter estimates the
number of prescriptions and the quantity of antibiotics indicates that both can
forecast the total payment made for Amoxicillin. About 91% of the time, the
variation in total payment is explained by both the quantity and the number of
antibiotics. The R-square value close to one indicates that both the predictor
variables, quantity and number of prescriptions, predict the total payment.
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Hence, the model prediction for total payment can include the quantity of
antibiotic and the number of prescriptions. We also plotted the model forecast for
total payment using the quantity of antibiotic and the number of prescriptions as
predictors.
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Figure 7.36. Prediction of Total Payment using Quantity and Number of Prescriptions for
Amoxicillin.

When we introduced the quantity of prescriptions and the number of prescriptions
as predictor variables for total payment for the prescription of Amoxicillin, the R2
value dramatically increased from -0.094 to 0.9117; this is a great improvement
of the predictor variables’ influence on the total payment of Amoxicillin. Also,
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when compared to total payments made for Amoxicillin without the predictor
variable (figure 7.8), figure 7.36 gave a better forecast plot with the total payment
seasonally increasing or decreasing as we move from January, 1996 up to
December, 2006.

Patient Condition Severity

We then used text mining with kernel density estimation to reduce a large
number of patient condition codes to make a comparison between the severity of
the patient condition on the use of antibiotics. We condensed thousands of
patient conditions into an index of 6 levels, and those levels are used to examine
the relationship to different target variables of total payment and private
insurance payments. Since there are hundreds of ICD-9 codes, and most
patients have more than one ICD-9 code assigned to them, we compress the
codes into a total of six clusters. We applied clustering and text mining to group
similar patients together so that meaningful analyses can be performed examine
cost. We used text mining to process and analyze the ICD-9 codes and to find
similarities between patients. We then group similar patients together.

Clustering was performed using the expectation maximization algorithm. It is a
relatively new, iterative clustering technique that works well with nominal data in
comparison to the K-means and hierarchical methods that are more commonly
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used. Six clusters were formed using the ICD9 codes based on the similarity of
the text of each ICD-9 code.

Proc sort data = sasuser.Antibiotics out= work.sort_out;
by duid rxicd1x;
Run;

options obs=max;

Data work.sort_out1;
set work.sort_out;
icd9 = translate(left(trim(rxicd1x)),'_',' ');
Run;
proc Transpose data=work.sort_out1 out=work.tran
prefix=icd9_;
var icd9 ;
by duid;
run;
data work.concat( keep= duid icd9 ) ;
length icd9 $32767 ;
set work.tran ;
array rxconcat {*} icd9_: ;
icd9 = left( trim( icd_1 )) ;
do i = 2 to dim( rxconcat ) ;
icd9 = left(trim(icd9)) || ' ' || left(trim( rxconcat[i] )) ;
end ;
run ;

SAS CODE 15

Table 7.23 SAS code used to change ICD-9 codes to text and create clusters
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Proc sql ;
select max( length( icd9 )) into :icd9_LEN from work.concat ;
quit ;
%put icd9_LEN=&icd9_LEN ;
Data work.concat1 ;
length icd9 $ &icd9_LEN ;
set work.concat ;
Run ;
Proc contents data=work.concat1 ; Run; SAS CODE 15
Table 7.23 SAS code used to change ICD-9 codes to text and create clusters (continued)

Using SAS CODE 15, six clusters were formed based on the ICD9 codes using
Enterprise Miner 5.2. We created six clusters with the cluster number given in
table 7.24. We will use these clusters to compare the distribution of antibiotics
between the clusters using kernel density estimation. Table 7.25 is the
description of the clusters shown in table 7.24.
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#

Descriptive terms

Freq Percentage

1 601,562,786,487,465,596,522,496,892,785,575,996,784

760

0.79249218

2 716

2

0.00208551

3 599,593,382,388,493,595

38

0.03962461

4 473,490,519,401,429,477,592,491,311,686,919,428,492, 108

0.11261731

486,595,478,590
5 780,v68,460,41,v25,272,

19

0.0198123

6 244,518,998,590,493,486

32

0.03336809

Table 7.24 Clusters of the ICD-9 Codes
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Cluster
Number

ICD-9
Codes

1

601
562
786
487
465
596
522
496
892
785
575
996
784
716
599
593
382
388
493
595
473
490
519
401
429
477
592
491
311
686
919
428
492
486
595
478
590
780
v68
460
041
v25
272
244
518
998
590
493
486

2
3

4

5

6

ICD-9 Risk Factors
Prostatitis
Diverticula of Intestine
Respiratory & Chest symptom
Influenza
Upper respiratory infection acute
Bladder disorder
Pulp disease & peripheral tissues
Chronic airway obstruction
Open wound of foot
Symptoms involving cardiovascular system
Disorder of gallbladder
Anastomosis, graft (bypass), implant
Symptoms of head and neck
Other and unspecified arthropathies
Other disorders of urethra and urinary tract
Other disorders of kidney and ureter
Suppurative and unspecified otitis media
Other disorders of ear
Asthma
Cystitis
Chronic sinusitis
Bronchitis, not specifies as acute or chronic
Other diseases of respiratory system
Essential hypertension
Complications of heart disease
Allergic rhinitis, hay fever spasmodic rhinorrhea
Calculus of kidney and ureter
Chronic bronchitis
Depressive disorder
Local infections of skin and subcutaneous tissue
Superficial injury
Heart failure
Chronic obstructive pulmonary disease
Pneumonia, organism unspecified
Cystitis, other disease of urinary system
Other disease of upper respiratory tract
Infections of kidney
Alteration of consciousness, hallucinations
Persons encountering health service
Acute nasopharyngitis (common cold)
Bacterial infection
Contraceptive management, sterilization
Disorders of lipoid metabolism
Acquired hypothyroidism, like post-surgical
Diseases of lung, pulmonary collapse
Postoperative shock, hemorrhage
Infections of kidney
Asthma
Pneumonia

Frequency

Label

760

Routine
problems

2
38

Arthritis
Urinary tract
infection,
asthma

108

Severe
complications
of respiratory
system

19

Mild risk
factors

32

Moderate risk
factor

Table 7.25. Text Clusters Defined by Expectation Maximization
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We used kernel density estimation to examine differences within the six clusters.
Figures 7.24 and 7.25 are showing the graphs of total payments and private
insurance payments respectively by cluster id for the antibiotic, Cipro. Note that
cluster 2 has a high probability of total charges and reimbursements compared to
the other clusters where the amount is very low. These graphs demonstrate a
natural ordering in the clusters that is defined within the text mining tool.

Figure 7.37 Distributions of Total Payments for CIPRO

The clusters formed based on the severity of the patient condition were
compared using Kernel density estimation to examine total payments for the
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antibiotic, Cipro (Figure 7.37). For instance, for patients in cluster 3 taking Cipro,
they have a higher probability of paying between 40-80 dollars. As the total
payment exceeds 280 dollars, the severity of the disease does not play a role on
the size of payment made.

Figure 7.38 Distributions of Private Insurance Payments for CIPRO

The clusters formed based on the severity of the patient condition were
compared using Kernel density estimation to examine private insurance
payments for each antibiotic (Figure 7.38). For instance, for patients in cluster 3
taking Cipro, they have a higher probability of paying between 30-60 dollars but
patients in cluster 6 have a higher probability of paying between 115-180 dollars.
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Discussion
The rising cost of antibiotics is an important concern to health care providers and
to society. For many years, proper application of antibiotics has been difficult to
regulate and to control. Antibiotic costs have increased dramatically over the
years with an overall trend to prescribe expensive, broad spectrum antibiotics
rather than narrow-spectrum antibiotics. The term trend of antibiotics cost is
important knowledge to health care providers and insurance companies. The
trend analysis depends largely on an initial explanatory analysis of the data, and
in identifying the appropriate models to predict the trend. The best approach
currently available to model trend is to eliminate the trend by differencing and
data correction and to find an appropriate stationary model for the differenced
series.

Trend modeling requires finding the appropriate order of differencing, to correct
the data for missing values, and to identify the appropriate order of stationary
models for the differenced and corrected data 32. We have investigated the
changing behavior of the cost of antibiotics by introducing intervention variables.
Usually, the increase of cost is related to a certain event; for instance, when
September 11 happened, the airline industry lost tremendous amounts of
business as a consequence of people not traveling by air.
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In this dissertation, we are concerned not only with studying the increase in cost
of antibiotics, but also with a sudden shift (both increase and decrease) in the
cost of antibiotics. For instance, if we examine the private insurance payment
made for the antibiotic, Cipro, we observe that there was a constant increase
until a sudden and tremendous increase in September, 2002. Due to this
tremendous increase, the forecast for the future is influenced if we don’t take this
spike into consideration. As a result, we introduced point and step interventions.
A point intervention is assigned a value of one for September, 2002 and zero for
all other time points, while step intervention is to assign the value zero before
September, 2002 and assign a value of one for September, 2002–December,
2004.

We also analyzed the antibiotics data using GARCH models that take care of the
heteroskedasticity of the data. When applied to total payments made for
Erythromycin, the model built was fit much better compared to the ARIMA(1,2,0)
model that was fit earlier. We used inflation rate as a dynamic regressor, which
improved the model fit of the private insurance payment made for Cipro. Finally,
we analyzed the data using text mining and clustering the ICD 9 codes that
defined the patient condition, and made comparisons between the clusters
formed on the severity of the disease. We used kernel density estimation to plot
the six clusters on one plot for the antibiotic, Cipro, so that meaningful
comparisons could be made.
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CHAPTER 8
CONCLUSION

The aim of this dissertation was to develop time series models to investigate
prescribing practices and patient usage of antibiotics with respect to the severity
of the patient condition. We have analyzed factors that contribute to the cost of
antibiotics such as total payments and private insurance payments. The amount
of money spent varies between the severity of the patient condition; that means
that patients who are more severely ill spend more money for antibiotics
compared to patients who are less ill. Our goal was to develop time series
models so that we can compare between several antibiotics. To reach this
result, time series models and data mining tools such as text mining were used to
investigate the prescription of antibiotics.

The main analysis idea was to show that the increase in the cost of antibiotic is
affected by the increase in private insurance payment, and Medicare and
Medicaid payments made. There was also a tremendous change in the number
of prescriptions in one antibiotic compared to others.
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We also investigated a sudden change, which we call it an outlier or event in time
series theory. We found out that an outlier or an event does change the
predicted payments made for the antibiotics. We also studied the effect of the
inflation rate in cost of antibiotics, and found out the price prediction goes down.
Since most of the antibiotics we studied are already available in generic form, or
did not change to generic form during the time period under study, we could not
take the switch in type into consideration. However, such a switch would involve
a step function.

We also found out that the trends in the prescription of antibiotics were
increasing over the years 1996-2004. There is a difference in the number of
prescriptions of one antibiotic over another, with Amoxicillin mostly prescribed
and Vancomycin least prescribed. We also investigated how much patients are
spending on the sum and average for antibiotics and found out the spending was
increasing over the years, but increasing less than the inflation rate. We
examined the average Medicare and Medicaid payments for the antibiotic,
Cephalexin, and we found out that the predicted Medicaid payment is three times
as large as the Medicare payment. In terms of expenditure, the government’s
expense on Medicaid was increasing from the model forecast.

Text mining was used to reduce a large number of patient condition codes into
an index of 6 levels, and to use those levels to examine the relationship between
total payment and private insurance payments for different cluster levels.
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The results of this study can be used by health care institutions and
pharmaceutical companies to predict and forecast the distribution, cost, number
of prescriptions, quantity of prescription dose, private insurance payment,
Medicare payment and Medicaid payment. The trend of prescription can be used
to study what the effect really is on the decrease or increase in the prescriptions
of antibiotics.
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